<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Proteus syndrome - Disorder Mechanisms</title>
    <style>
        :root {
            --primary: #0f766e;
            --primary-light: #14b8a6;
            --primary-dark: #0d5c56;
            --secondary: #6366f1;
            --bg: #f0fdfa;
            --card-bg: #ffffff;
            --text: #134e4a;
            --text-muted: #5f7a78;
            --border: #ccfbf1;
            --accent-orange: #f59e0b;
            --accent-rose: #f43f5e;
            --accent-violet: #8b5cf6;
            --accent-sky: #0ea5e9;
            --banner-bg: #fef3c7;
            --banner-border: #f59e0b;
            --banner-text: #92400e;
        }

        * { box-sizing: border-box; margin: 0; padding: 0; }

        body {
            font-family: 'Segoe UI', system-ui, -apple-system, sans-serif;
            background: var(--bg);
            color: var(--text);
            line-height: 1.7;
        }

        .notice-banner {
            background: var(--banner-bg);
            color: var(--banner-text);
            border-bottom: 1px solid var(--banner-border);
            padding: 12px 16px;
            text-align: center;
            font-size: 0.95rem;
            cursor: pointer;
        }

        .container {
            max-width: 1100px;
            margin: 0 auto;
            padding: 24px;
        }

        /* Header */
        .page-header {
            background: linear-gradient(135deg, var(--primary) 0%, var(--primary-dark) 100%);
            color: white;
            padding: 40px 32px;
            border-radius: 16px;
            margin-bottom: 24px;
            position: relative;
            overflow: hidden;
        }

        .page-header::before {
            content: '';
            position: absolute;
            top: -50%;
            right: -20%;
            width: 400px;
            height: 400px;
            background: rgba(255,255,255,0.05);
            border-radius: 50%;
        }

        .page-header h1 {
            font-size: 2.2rem;
            font-weight: 700;
            margin-bottom: 12px;
            position: relative;
        }

        .header-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 12px;
            align-items: center;
            position: relative;
        }

        .badge {
            display: inline-flex;
            align-items: center;
            padding: 6px 14px;
            border-radius: 20px;
            font-size: 0.85rem;
            font-weight: 500;
        }

        .badge-category {
            background: rgba(255,255,255,0.2);
            color: white;
        }

        .badge-mondo {
            background: var(--accent-sky);
            color: white;
        }

        .badge-mondo a {
            color: inherit;
            text-decoration: none;
        }

        .badge-mondo a:hover {
            text-decoration: underline;
        }

        /* Navigation */
        .breadcrumb {
            margin-bottom: 16px;
            font-size: 0.9rem;
        }

        .breadcrumb a {
            color: var(--primary);
            text-decoration: none;
        }

        .breadcrumb a:hover {
            text-decoration: underline;
        }

        .breadcrumb span {
            color: var(--text-muted);
        }

        /* Cards */
        .card {
            background: var(--card-bg);
            border-radius: 12px;
            border: 1px solid var(--border);
            padding: 24px;
            margin-bottom: 20px;
            box-shadow: 0 1px 3px rgba(0,0,0,0.04);
        }

        .card-header {
            display: flex;
            align-items: center;
            gap: 12px;
            margin-bottom: 16px;
            padding-bottom: 12px;
            border-bottom: 2px solid var(--border);
        }

        .card-icon {
            width: 36px;
            height: 36px;
            border-radius: 8px;
            display: flex;
            align-items: center;
            justify-content: center;
            font-size: 1.2rem;
        }

        .card-title {
            font-size: 1.1rem;
            font-weight: 600;
            color: var(--text);
        }

        .card-count {
            margin-left: auto;
            background: var(--bg);
            padding: 4px 12px;
            border-radius: 12px;
            font-size: 0.8rem;
            color: var(--text-muted);
        }

        /* Sections */
        .section-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(320px, 1fr));
            gap: 20px;
        }

        /* Tags */
        .tag-list {
            display: flex;
            flex-wrap: wrap;
            gap: 8px;
        }

        .tag {
            padding: 6px 12px;
            border-radius: 6px;
            font-size: 0.85rem;
            font-weight: 500;
        }

        .tag-cell {
            background: #fce7f3;
            color: #9d174d;
        }

        .tag-gene {
            background: #dbeafe;
            color: #1e40af;
        }

        .tag-treatment {
            background: #ede9fe;
            color: #5b21b6;
        }

        .tag-env {
            background: #ccfbf1;
            color: #0f766e;
        }

        .tag-location {
            background: #e0e7ff;
            color: #3730a3;
        }

        .tag-component {
            background: #f0fdf4;
            color: #166534;
        }

        .tag-complex {
            background: #faf5ff;
            color: #7e22ce;
        }

        .tag-bio {
            background: #fef3c7;
            color: #92400e;
        }

        .tag-modifier {
            background: #fee2e2;
            color: #991b1b;
            text-transform: uppercase;
            letter-spacing: 0.02em;
        }

        .tag-parent {
            background: #e0e7ff;
            color: #3730a3;
        }

        .tag-classification {
            background: #fef3c7;
            color: #92400e;
        }

        .tag-mechanistic {
            background: #dbeafe;
            color: #1e40af;
        }

        .linkout {
            color: inherit;
            margin-left: 6px;
            font-size: 0.75rem;
            text-decoration: none;
            border-bottom: 1px dotted rgba(0, 0, 0, 0.2);
        }

        .classification-category {
            font-size: 0.75rem;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.05em;
            color: var(--text-muted);
            margin-bottom: 8px;
        }

        .mapping-section {
            margin-bottom: 16px;
        }

        .mapping-item {
            padding: 10px 12px;
            border: 1px solid #e2e8f0;
            border-radius: 8px;
            background: #ffffff;
            margin-bottom: 10px;
        }

        .mapping-title {
            font-size: 0.9rem;
            font-weight: 600;
            display: flex;
            flex-wrap: wrap;
            gap: 8px;
            align-items: baseline;
            margin-bottom: 6px;
        }

        .mapping-label {
            color: var(--text-muted);
            font-weight: 500;
        }

        .mapping-notes {
            font-size: 0.85rem;
            color: var(--text-muted);
            margin-top: 6px;
        }

        .mapping-tree {
            margin-top: 6px;
            font-size: 0.75rem;
            color: var(--text-muted);
            list-style: none;
            padding-left: 0;
        }

        .mapping-tree li {
            margin: 2px 0;
        }

        /* Evidence styling */
        .evidence-toggle {
            cursor: pointer;
            font-size: 0.8rem;
            color: var(--text-muted);
            margin-top: 10px;
            user-select: none;
        }

        .evidence-toggle:hover {
            color: var(--primary);
        }

        .evidence-list {
            margin-top: 10px;
            padding-left: 0;
        }

        .evidence-item {
            padding: 12px 14px;
            background: #f8fafc;
            border-radius: 8px;
            margin-bottom: 8px;
            border: 1px solid #e2e8f0;
            font-size: 0.9rem;
        }

        .evidence-header {
            display: flex;
            align-items: center;
            flex-wrap: wrap;
            gap: 8px;
        }

        .evidence-ref {
            font-weight: 600;
            color: var(--secondary);
        }

        .evidence-ref a {
            color: inherit;
            text-decoration: none;
        }

        .evidence-ref a:hover {
            text-decoration: underline;
        }

        .evidence-support {
            font-size: 0.7rem;
            padding: 2px 8px;
            border-radius: 4px;
            font-weight: 600;
            text-transform: uppercase;
            transition: transform 120ms ease, box-shadow 120ms ease;
        }

        .support-SUPPORT { background: #dcfce7; color: #166534; }
        .support-PARTIAL { background: #fef3c7; color: #92400e; }
        .support-REFUTE { background: #fee2e2; color: #991b1b; }
        .support-NO_EVIDENCE { background: #f1f5f9; color: #64748b; }
        .support-WRONG_STATEMENT { background: #fecaca; color: #7f1d1d; }

        .evidence-source {
            font-size: 0.7rem;
            padding: 2px 8px;
            border-radius: 4px;
            font-weight: 600;
            text-transform: uppercase;
            background: #e2e8f0;
            color: #334155;
            transition: transform 120ms ease, box-shadow 120ms ease;
        }

        .evidence-support:hover,
        .evidence-source:hover {
            transform: translateY(-1px);
            box-shadow: 0 4px 10px rgba(0,0,0,0.08);
        }

        .source-HUMAN_CLINICAL { background: #e0f2fe; color: #075985; }
        .source-MODEL_ORGANISM { background: #fef9c3; color: #854d0e; }
        .source-IN_VITRO { background: #ede9fe; color: #5b21b6; }
        .source-COMPUTATIONAL { background: #cffafe; color: #0e7490; }
        .source-OTHER { background: #e5e7eb; color: #374151; }

        .evidence-snippet {
            font-size: 0.85rem;
            color: var(--text-muted);
            margin-top: 8px;
            padding-left: 12px;
            border-left: 2px solid #cbd5e1;
            font-style: italic;
            line-height: 1.5;
        }

        .evidence-explanation {
            font-size: 0.85rem;
            color: var(--text);
            margin-top: 6px;
            line-height: 1.5;
        }

        .evidence-more {
            font-size: 0.8rem;
            color: var(--text-muted);
            margin-top: 6px;
            font-style: italic;
        }

        .findings-section {
            margin-top: 12px;
        }

        .findings-title {
            font-size: 0.75rem;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.04em;
            color: var(--text-muted);
            margin-bottom: 6px;
        }

        .finding-item {
            padding: 10px 12px;
            background: #f8fafc;
            border-radius: 8px;
            margin-bottom: 8px;
            border: 1px solid #e2e8f0;
            font-size: 0.9rem;
        }

        .finding-statement {
            font-weight: 600;
            color: var(--text);
            margin-bottom: 6px;
            line-height: 1.5;
        }

        .finding-supporting {
            font-size: 0.85rem;
            color: var(--text-muted);
            margin-top: 6px;
            padding-left: 12px;
            border-left: 2px solid #cbd5e1;
            font-style: italic;
            line-height: 1.5;
        }

        /* Item containers with evidence */
        .item-box {
            padding: 16px;
            border-radius: 10px;
            margin-bottom: 12px;
        }

        .item-name {
            font-weight: 600;
            margin-bottom: 6px;
        }

        .item-desc {
            font-size: 0.9rem;
            line-height: 1.6;
            margin-bottom: 8px;
        }

        .item-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 6px;
            margin-top: 8px;
        }

        /* Definitions */
        .definition-box {
            background: #ecfeff;
            border-left: 4px solid #0ea5e9;
        }
        .definition-box .item-name { color: #0c4a6e; }
        .definition-box .item-desc { color: #075985; }

        /* Inheritance */
        .inheritance-box {
            background: #fef9c3;
            border-left: 4px solid #ca8a04;
        }
        .inheritance-box .item-name { color: #92400e; }
        .inheritance-box .item-desc { color: #92400e; }

        .criteria-block {
            margin-top: 12px;
            padding: 12px;
            border-radius: 8px;
            border: 1px solid #bae6fd;
            background: rgba(255, 255, 255, 0.7);
        }

        .criteria-title {
            font-weight: 600;
            color: #0c4a6e;
            margin-bottom: 6px;
        }

        .criteria-meta {
            font-size: 0.8rem;
            color: var(--text-muted);
            margin-bottom: 8px;
        }

        .criteria-header {
            font-size: 0.75rem;
            text-transform: uppercase;
            letter-spacing: 0.04em;
            color: #0284c7;
            margin-top: 8px;
        }

        .criteria-list {
            margin-left: 18px;
            font-size: 0.9rem;
            line-height: 1.5;
            color: #0f172a;
        }

        .criteria-list li {
            margin-bottom: 6px;
        }

        .criteria-detail {
            display: block;
            font-size: 0.85rem;
            color: var(--text-muted);
        }

        /* Pathophysiology */
        .pathophys-box {
            background: linear-gradient(135deg, #fef3c7 0%, #fef9c3 100%);
            border-left: 4px solid var(--accent-orange);
        }
        .pathophys-box .item-name { color: #92400e; }
        .pathophys-box .item-desc { color: #78350f; }

        /* Histopathology */
        .histopathology-box {
            background: #fff7ed;
            border-left: 4px solid #fb923c;
        }
        .histopathology-box .item-name { color: #9a3412; }
        .histopathology-box .item-desc { color: #c2410c; }

        .histopathology-freq {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #ffedd5;
            color: #c2410c;
        }

        /* Phenotypes */
        .phenotype-box {
            background: #f0fdf4;
            border-left: 4px solid #22c55e;
        }
        .phenotype-box .item-name { color: #166534; }
        .phenotype-box .item-desc { color: #15803d; }

        .phenotype-freq {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #dcfce7;
            color: #15803d;
        }

        .phenotype-category {
            font-size: 0.75rem;
            color: #4ade80;
        }

        .phenotype-id a {
            font-size: 0.8rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .phenotype-id a:hover {
            text-decoration: underline;
        }

        /* Phenotype TOC strip */
        .pheno-toc {
            display: flex;
            flex-wrap: wrap;
            gap: 6px;
            padding: 10px 0 6px 0;
            border-bottom: 1px solid #e2e8f0;
            margin-bottom: 4px;
        }

        .pheno-toc-pill {
            display: inline-block;
            font-size: 0.78rem;
            padding: 3px 10px;
            border-radius: 12px;
            background: #dcfce7;
            color: #166534;
            text-decoration: none;
            cursor: pointer;
            white-space: nowrap;
            transition: background 0.15s;
        }

        .pheno-toc-pill:hover {
            background: #bbf7d0;
        }

        .pheno-toc-pill .pill-count {
            font-weight: 600;
            margin-left: 2px;
        }

        .pheno-toggle-all {
            font-size: 0.78rem;
            color: #16a34a;
            cursor: pointer;
            background: none;
            border: 1px solid #bbf7d0;
            border-radius: 6px;
            padding: 3px 10px;
            margin-left: auto;
            white-space: nowrap;
            transition: background 0.15s;
        }

        .pheno-toggle-all:hover {
            background: #f0fdf4;
        }

        /* Collapsible category groups */
        .phenotype-category-group {
            margin-bottom: 2px;
        }

        .phenotype-category-group summary {
            font-size: 0.85rem;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.04em;
            color: #16a34a;
            margin: 0;
            padding: 10px 0 6px 0;
            border-bottom: 1px solid #bbf7d0;
            cursor: pointer;
            list-style: none;
            display: flex;
            align-items: center;
            gap: 6px;
        }

        .phenotype-category-group summary::-webkit-details-marker {
            display: none;
        }

        .phenotype-category-group summary .chevron {
            display: inline-block;
            width: 16px;
            height: 16px;
            transition: transform 0.15s;
            flex-shrink: 0;
        }

        .phenotype-category-group[open] summary .chevron {
            transform: rotate(90deg);
        }

        .phenotype-category-group summary .cat-count {
            font-size: 0.75rem;
            font-weight: 400;
            color: #15803d;
            background: #dcfce7;
            padding: 1px 7px;
            border-radius: 8px;
        }

        /* Phenotype Contexts */
        .phenotype-contexts {
            margin-top: 10px;
        }

        .phenotype-contexts-toggle {
            font-size: 0.8rem;
            color: var(--text-muted);
            cursor: pointer;
            user-select: none;
        }

        .phenotype-contexts-toggle:hover {
            color: var(--primary);
        }

        .context-card {
            padding: 10px 14px;
            margin-top: 8px;
            border-radius: 8px;
            background: #ecfdf5;
            border: 1px solid #a7f3d0;
            font-size: 0.88rem;
        }

        .context-header {
            display: flex;
            flex-wrap: wrap;
            align-items: center;
            gap: 6px;
            margin-bottom: 6px;
        }

        .context-label {
            font-size: 0.72rem;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.04em;
            padding: 2px 8px;
            border-radius: 4px;
        }

        .context-label-genetic {
            background: #dbeafe;
            color: #1e40af;
        }

        .context-label-sex {
            background: #fce7f3;
            color: #9d174d;
        }

        .context-label-population {
            background: #fef3c7;
            color: #92400e;
        }

        .context-label-age {
            background: #e0e7ff;
            color: #3730a3;
        }

        .context-label-subtype {
            background: #ede9fe;
            color: #5b21b6;
        }

        .context-label-frequency {
            background: #dcfce7;
            color: #166534;
        }

        .context-gene-list {
            display: flex;
            flex-wrap: wrap;
            gap: 4px;
            margin: 4px 0;
        }

        .context-gene-tag {
            font-size: 0.78rem;
            font-weight: 600;
            padding: 1px 8px;
            border-radius: 4px;
            background: #bfdbfe;
            color: #1e3a8a;
        }

        .context-detail {
            font-size: 0.84rem;
            color: #065f46;
            line-height: 1.5;
        }

        .context-detail strong {
            color: #047857;
        }

        .context-freq {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #bbf7d0;
            color: #14532d;
            font-weight: 600;
        }

        .context-onset {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #e0e7ff;
            color: #3730a3;
        }

        .context-severity {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #fef3c7;
            color: #92400e;
        }

        .context-notes {
            font-size: 0.84rem;
            color: #065f46;
            margin-top: 4px;
            line-height: 1.5;
        }

        /* Genetic */
        .genetic-box {
            background: #eff6ff;
            border-left: 4px solid #3b82f6;
        }
        .genetic-box .item-name { color: #1e40af; }
        .genetic-box .item-desc { color: #2563eb; }

        /* Treatment */
        .treatment-box {
            background: #faf5ff;
            border-left: 4px solid #8b5cf6;
        }
        .treatment-box .item-name { color: #5b21b6; }
        .treatment-box .item-desc { color: #7c3aed; }

        /* Environmental */
        .environmental-box {
            background: #f0fdfa;
            border-left: 4px solid #14b8a6;
        }
        .environmental-box .item-name { color: #0f766e; }
        .environmental-box .item-desc { color: #0d9488; }

        /* Biochemical */
        .biochemical-box {
            background: #fffbeb;
            border-left: 4px solid #f59e0b;
        }
        .biochemical-box .item-name { color: #92400e; }
        .biochemical-box .item-desc { color: #b45309; }

        /* Differential Diagnoses */
        .differential-box {
            background: #fef2f2;
            border-left: 4px solid #dc2626;
        }
        .differential-box .item-name { color: #7f1d1d; }
        .differential-box .item-desc { color: #b91c1c; }

        .differential-similarities {
            background: #fee2e2;
            border-left: 2px solid #dc2626;
            padding: 10px 12px;
            border-radius: 6px;
            margin: 8px 0;
            font-size: 0.9rem;
        }

        .differential-distinctions {
            background: #dcfce7;
            border-left: 2px solid #16a34a;
            padding: 10px 12px;
            border-radius: 6px;
            margin: 8px 0;
            font-size: 0.9rem;
        }

        .differential-similarities strong,
        .differential-distinctions strong {
            display: block;
            margin-bottom: 6px;
            font-size: 0.85rem;
            text-transform: uppercase;
            letter-spacing: 0.05em;
        }

        .differential-similarities ul,
        .differential-distinctions ul {
            margin-left: 16px;
            line-height: 1.6;
        }

        .differential-similarities li,
        .differential-distinctions li {
            margin: 4px 0;
            font-size: 0.9rem;
        }

        /* Datasets */
        .dataset-box {
            background: #f0f9ff;
            border-left: 4px solid #0284c7;
        }
        .dataset-box .item-name { color: #0c4a6e; }
        .dataset-box .item-desc { color: #0369a1; }

        .tag-dataset {
            background: #e0f2fe;
            color: #0369a1;
        }

        .tag-organism {
            background: #fae8ff;
            color: #a21caf;
        }

        .tag-datatype {
            background: #dbeafe;
            color: #1d4ed8;
        }

        /* Clinical Trials */
        .clinical-trial-box {
            background: #f5f3ff;
            border-left: 4px solid #a855f7;
        }
        .clinical-trial-box .item-name { color: #6b21a8; }
        .clinical-trial-box .item-desc { color: #7e22ce; }

        .tag-phase {
            background: #ede9fe;
            color: #6b21a8;
        }

        .tag-status {
            background: #fce7f3;
            color: #9d174d;
        }

        .trial-nct a {
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .trial-nct a:hover {
            text-decoration: underline;
        }

        .dataset-accession a {
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .dataset-accession a:hover {
            text-decoration: underline;
        }

        /* Subtypes */
        .subtype-box {
            background: #eef2ff;
            border-left: 4px solid var(--secondary);
        }
        .subtype-box .item-name { color: #3730a3; }
        .subtype-box .item-desc { color: #4f46e5; }
        .classification-header {
            font-size: 1rem;
            font-weight: 600;
            color: #4338ca;
            margin: 1.2rem 0 0.5rem 0;
            padding-bottom: 0.3rem;
            border-bottom: 2px solid #c7d2fe;
            text-transform: capitalize;
        }
        .subtype-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 0.4rem;
            margin: 0.3rem 0;
        }
        .subtype-freq-badge {
            background: #dbeafe;
            color: #1e40af;
            padding: 0.15rem 0.5rem;
            border-radius: 9999px;
            font-size: 0.8rem;
            font-weight: 500;
        }
        .subtype-gene-tag {
            background: #fef3c7;
            color: #92400e;
            padding: 0.15rem 0.5rem;
            border-radius: 9999px;
            font-size: 0.8rem;
            font-weight: 500;
        }
        .subtype-inheritance-tag {
            background: #ede9fe;
            color: #5b21b6;
            padding: 0.15rem 0.5rem;
            border-radius: 9999px;
            font-size: 0.8rem;
            font-weight: 500;
        }
        .subtype-term-link {
            font-size: 0.8rem;
            color: #6366f1;
            text-decoration: none;
        }
        .subtype-term-link:hover { text-decoration: underline; }
        .subtype-children {
            margin: 0.4rem 0 0.2rem 1rem;
            padding: 0;
            list-style: none;
        }
        .subtype-children li {
            font-size: 0.85rem;
            color: #4338ca;
            padding: 0.1rem 0;
        }
        .subtype-children li::before {
            content: "↳ ";
            color: #a5b4fc;
        }

        /* Stats bar */
        .stats-bar {
            display: flex;
            gap: 24px;
            padding: 20px 24px;
            background: var(--card-bg);
            border-radius: 12px;
            border: 1px solid var(--border);
            margin-bottom: 24px;
            flex-wrap: wrap;
        }

        .stat-item {
            text-align: center;
        }

        .stat-link {
            text-decoration: none;
            color: inherit;
        }

        .stat-value {
            font-size: 1.5rem;
            font-weight: 700;
            color: var(--primary);
        }

        .stat-label {
            font-size: 0.8rem;
            color: var(--text-muted);
            text-transform: uppercase;
            letter-spacing: 0.05em;
        }

        /* YAML preview */
        .yaml-preview {
            background: #1e293b;
            color: #e2e8f0;
            padding: 20px;
            border-radius: 8px;
            overflow-x: auto;
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            line-height: 1.5;
            max-height: 400px;
            overflow-y: auto;
        }

        .yaml-content {
            display: none;
        }

        .yaml-content.show {
            display: block;
        }

        /* Footer */
        .page-footer {
            margin-top: 40px;
            padding-top: 20px;
            border-top: 1px solid var(--border);
            text-align: center;
            color: var(--text-muted);
            font-size: 0.85rem;
        }

        .page-footer a {
            color: var(--primary);
            text-decoration: none;
        }

        .page-footer a:hover {
            text-decoration: underline;
        }

        /* Responsive */
        @media (max-width: 768px) {
            .page-header h1 { font-size: 1.6rem; }
            .stats-bar { gap: 16px; }
            .section-grid { grid-template-columns: 1fr; }
        }
        /* Mermaid graph */
        .mermaid-container {
            text-align: center;
            margin: 20px 0;
            padding: 20px;
            background: white;
            border-radius: 8px;
            border: 1px solid var(--border);
            overflow-x: auto;
        }

        .mermaid svg {
            max-width: 100%;
            height: auto;
        }

        .graph-warning {
            background: #fef3c7;
            border: 1px solid #f59e0b;
            border-radius: 8px;
            padding: 12px 16px;
            margin-bottom: 16px;
            font-size: 0.85rem;
            color: #92400e;
        }

        .graph-warning strong {
            display: block;
            margin-bottom: 4px;
        }

        .graph-warning ul {
            margin: 8px 0 0 20px;
            padding: 0;
        }

        .graph-warning li {
            margin: 4px 0;
        }
    </style>
    <script src="https://cdn.jsdelivr.net/npm/mermaid@10/dist/mermaid.min.js"></script>
    <script>
        mermaid.initialize({
            startOnLoad: true,
            theme: 'default',
            flowchart: {
                htmlLabels: true,
                curve: 'basis'
            }
        });
    </script>
</head>
<body>
    <div class="notice-banner" role="button" tabindex="0">This resource is in its pre-alpha development stage. Content is actively being curated and may be incomplete or subject to change.</div>
    

    

    
    

    
    

    

    

    

    

    

    <div class="container">
        <nav class="breadcrumb">
            <a href="../../app/index.html">Browse All</a>
            <span> / </span>
            <span>Proteus syndrome</span>
        </nav>

        <header class="page-header">
            <h1>Proteus syndrome</h1>
            <div class="header-meta">
                
                <span class="badge badge-category">Mendelian</span>
                
                
                <span class="badge badge-mondo">
                    <a href="http://purl.obolibrary.org/obo/MONDO_0008318" target="_blank">
                        MONDO:0008318
                    </a>
                </span>
                
                
            </div>
            
        </header>

        <!-- Stats bar -->
        
        
        
        
        
        
        
        
        
        
        
        
        
        <div class="stats-bar">
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Mappings</div>
            </div>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Definitions</div>
            </div>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Inheritance</div>
            </div>
            
            
            <a class="stat-link" href="#pathophysiology">
            <div class="stat-item">
                <div class="stat-value">6</div>
                <div class="stat-label">Pathophysiology</div>
            </div>
            </a>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Histopathology</div>
            </div>
            
            
            <a class="stat-link" href="#phenotypes">
            <div class="stat-item">
                <div class="stat-value">22</div>
                <div class="stat-label">Phenotypes</div>
            </div>
            </a>
            
            
            <a class="stat-link" href="#genetic">
            <div class="stat-item">
                <div class="stat-value">1</div>
                <div class="stat-label">Genes</div>
            </div>
            </a>
            
            
            <a class="stat-link" href="#treatments">
            <div class="stat-item">
                <div class="stat-value">2</div>
                <div class="stat-label">Treatments</div>
            </div>
            </a>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Subtypes</div>
            </div>
            
            
            <a class="stat-link" href="#differentials">
            <div class="stat-item">
                <div class="stat-value">6</div>
                <div class="stat-label">Differentials</div>
            </div>
            </a>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Datasets</div>
            </div>
            
            
            <a class="stat-link" href="#trials">
            <div class="stat-item">
                <div class="stat-value">6</div>
                <div class="stat-label">Trials</div>
            </div>
            </a>
            
        </div>

        <!-- Classifications -->
        

        <!-- Mappings -->
        

        <!-- Definitions -->
        

        <!-- Inheritance -->
        

        <!-- Subtypes -->
        

        <!-- Comorbidities -->
        

        <!-- Pathophysiology -->
        
        <div class="card" id="pathophysiology">
            <div class="card-header">
                <div class="card-icon" style="background: #fef3c7; color: #d97706;">⚙</div>
                <h2 class="card-title">Pathophysiology</h2>
                <span class="card-count">6</span>
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Somatic AKT1 p.E17K activation in mosaic cell clones</div>
                
                <div class="item-desc">Proteus syndrome is caused by a post-zygotic activating AKT1 p.E17K variant present in a mosaic subset of cells.
</div>
                
                
                
                
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://bioregistry.io/DOI:10.1038/srep17162" target="_blank">DOI:10.1038/srep17162</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"A somatic activating mutation in AKT1, c.49G&gt;A, pGlu17Lys, that results in elevated AKT signaling in mutation-positive cells, is responsible for the mosaic overgrowth condition, Proteus syndrome."</div>
                
                
                <div class="evidence-explanation">This establishes mosaic, somatic AKT1 p.E17K activation in Proteus syndrome.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Elevated PI3K/AKT signaling in AKT1-mutant cells</div>
                
                <div class="item-desc">AKT1 p.E17K drives increased PI3K/AKT pathway activity in mutation-positive cells, promoting downstream overgrowth signals.
</div>
                
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        phosphatidylinositol 3-kinase/protein kinase B signal transduction
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0043491" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    <span class="tag tag-modifier">
        ↑ INCREASED
    </span>
    
    
                    
                </div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://bioregistry.io/DOI:10.1038/srep17162" target="_blank">DOI:10.1038/srep17162</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"A somatic activating mutation in AKT1, c.49G&gt;A, pGlu17Lys, that results in elevated AKT signaling in mutation-positive cells, is responsible for the mosaic overgrowth condition, Proteus syndrome."</div>
                
                
                <div class="evidence-explanation">This directly links AKT1 activation to elevated AKT signaling in mutation-positive cells.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Increased pAKT signaling in AKT1-mutant lesion cells</div>
                
                <div class="item-desc">Lesion cells harboring AKT1 p.E17K show increased pAKT signaling within hyperplastic regions.
</div>
                
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        protein phosphorylation
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0006468" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    <span class="tag tag-modifier">
        ↑ INCREASED
    </span>
    
    
                    
                </div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://bioregistry.io/DOI:10.1093/hmg/ddz116" target="_blank">DOI:10.1093/hmg/ddz116</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Identification of variant-positive cells by green fluorescent protein (GFP) staining in chimeric Proteus syndrome mice showed that in some lesions, hyperplastic cells were predominantly GFP/Akt1E17K-positive and showed increased pAKT signal compared to GFP-negative cells."</div>
                
                
                <div class="evidence-explanation">This demonstrates increased pAKT signaling in mutant clones within lesions.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Non-cell-autonomous pAKT activation in adjacent cells</div>
                
                <div class="item-desc">AKT1-mutant clones can induce increased pAKT signaling in nearby mutation-negative cells, consistent with non-cell-autonomous lesion propagation.
</div>
                
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        cell-cell signaling
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0007267" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    <span class="tag tag-modifier">
        ↑ INCREASED
    </span>
    
    
                    
                </div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://bioregistry.io/DOI:10.1093/hmg/ddz116" target="_blank">DOI:10.1093/hmg/ddz116</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"However, hyperplastic mammary epithelium was a mixture of GFP/Akt1E17K-positive and negative cells with some GFP/Akt1E17K-negative cells also having increased pAKT signal suggesting that the variant-positive cells can induce lesion formation in a non-cell autonomous manner."</div>
                
                
                <div class="evidence-explanation">This provides evidence for non-cell-autonomous effects in lesion formation.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">AKT overactivation induces excessive vasculogenesis</div>
                
                <div class="item-desc">AKT1 activation increases vascular connectivity and promotes vasculogenesis with enhanced vascular sprouting.
</div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-cell">
                        endothelial cell
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0000115" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        vasculogenesis
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0001570" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    <span class="tag tag-modifier">
        ↑ INCREASED
    </span>
    
    
                    
                    <span class="tag tag-bio">
                        angiogenesis
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0001525" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    <span class="tag tag-modifier">
        ↑ INCREASED
    </span>
    
    
                    
                </div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://bioregistry.io/DOI:10.1101/2024.01.26.577324" target="_blank">DOI:10.1101/2024.01.26.577324</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Our findings revealed that AKT overactivation in these organoids resulted in smaller sizes yet increased vascular connectivity, although with less stable connections."</div>
                
                
                <div class="evidence-explanation">AKT overactivation increases vascular connectivity in organoid vasculature.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://bioregistry.io/DOI:10.1101/2024.01.26.577324" target="_blank">DOI:10.1101/2024.01.26.577324</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"This could be due to the significant vasculogenesis induced by AKT overactivation."</div>
                
                
                <div class="evidence-explanation">The study explicitly links AKT overactivation to increased vasculogenesis.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Mural cell dysfunction destabilizes vascular connections</div>
                
                <div class="item-desc">AKT-driven vascular malformations include dysfunctional PDGFRβ+ mural cells with impaired matrix secretion, contributing to unstable vessel connections.
</div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-cell">
                        pericyte
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0000669" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        extracellular matrix organization
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0030198" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    <span class="tag tag-modifier">
        ↓ DECREASED
    </span>
    
    
                    
                </div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://bioregistry.io/DOI:10.1101/2024.01.26.577324" target="_blank">DOI:10.1101/2024.01.26.577324</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Our findings revealed that AKT overactivation in these organoids resulted in smaller sizes yet increased vascular connectivity, although with less stable connections."</div>
                
                
                <div class="evidence-explanation">AKT overactivation is linked to unstable vascular connections.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://bioregistry.io/DOI:10.1101/2024.01.26.577324" target="_blank">DOI:10.1101/2024.01.26.577324</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Additionally, a notable increase in dysfunctional PDGFRβ + mural cells, impaired in matrix secretion, was observed in these AKT-overactivated organoids."</div>
                
                
                <div class="evidence-explanation">This supports mural cell dysfunction as part of the vascular phenotype.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Histopathology -->
        

        <!-- Causal Graph -->
        

        <!-- Phenotypes -->
        
        <div class="card" id="phenotypes">
            <div class="card-header">
                <div class="card-icon" style="background: #dcfce7; color: #16a34a;">●</div>
                <h2 class="card-title">Phenotypes</h2>
                <span class="card-count">22</span>
            </div>
            
            
            <div class="pheno-toc">
                
                <a class="pheno-toc-pill" data-target="pheno-cat-1">Blood<span class="pill-count">(1)</span></a>
                
                <a class="pheno-toc-pill" data-target="pheno-cat-2">Cardiovascular<span class="pill-count">(3)</span></a>
                
                <a class="pheno-toc-pill" data-target="pheno-cat-3">Eye<span class="pill-count">(7)</span></a>
                
                <a class="pheno-toc-pill" data-target="pheno-cat-4">Integument<span class="pill-count">(2)</span></a>
                
                <a class="pheno-toc-pill" data-target="pheno-cat-5">Musculoskeletal<span class="pill-count">(3)</span></a>
                
                <a class="pheno-toc-pill" data-target="pheno-cat-6">Respiratory<span class="pill-count">(2)</span></a>
                
                <a class="pheno-toc-pill" data-target="pheno-cat-7">Constitutional<span class="pill-count">(1)</span></a>
                
                <a class="pheno-toc-pill" data-target="pheno-cat-8">Growth<span class="pill-count">(2)</span></a>
                
                <a class="pheno-toc-pill" data-target="pheno-cat-9">Neoplasm<span class="pill-count">(1)</span></a>
                
                <button class="pheno-toggle-all" id="phenoToggleAll">Expand all</button>
            </div>
            
            
            <details class="phenotype-category-group" id="pheno-cat-1">
                <summary>
                    <svg class="chevron" viewBox="0 0 16 16" fill="currentColor"><path d="M6 3l5 5-5 5V3z"/></svg>
                    Blood
                    <span class="cat-count">1</span>
                </summary>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Deep vein thrombosis
                        
                        <span class="phenotype-freq">FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0002625" target="_blank">
                                Deep venous thrombosis
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0002625)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/22876373" target="_blank">PMID:22876373</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"It is associated with a range of tumors, pulmonary complications, and a striking predisposition to deep vein thrombosis and pulmonary embolism."</div>
                
                
                <div class="evidence-explanation">GeneReviews documents a predisposition to deep vein thrombosis in Proteus syndrome.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/33987133" target="_blank">PMID:33987133</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Thus, Proteus syndrome patients are at risk of developing deep vein thrombosis and pulmonary embolism."</div>
                
                
                <div class="evidence-explanation">This case report confirms thrombotic risk in Proteus syndrome.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
            </details>
            
            <details class="phenotype-category-group" id="pheno-cat-2">
                <summary>
                    <svg class="chevron" viewBox="0 0 16 16" fill="currentColor"><path d="M6 3l5 5-5 5V3z"/></svg>
                    Cardiovascular
                    <span class="cat-count">3</span>
                </summary>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Venous malformation
                        
                        <span class="phenotype-freq">FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0012721" target="_blank">
                                Venous malformation
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0012721)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://bioregistry.io/DOI:10.1093/hmg/ddz116" target="_blank">DOI:10.1093/hmg/ddz116</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Common manifestations include skin and bony overgrowth, vascular malformations (VMs), cysts and benign tumors."</div>
                
                
                <div class="evidence-explanation">This lists vascular malformations among common Proteus syndrome manifestations.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/33987133" target="_blank">PMID:33987133</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Many individuals develop cutaneous capillary malformation and prominent varicosities (large and complex vascular malformations)."</div>
                
                
                <div class="evidence-explanation">This documents vascular malformations with prominent varicosities in Proteus syndrome.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Varicose veins
                        
                        <span class="phenotype-freq">FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0002619" target="_blank">
                                Varicose veins
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0002619)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/33987133" target="_blank">PMID:33987133</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Many individuals develop cutaneous capillary malformation and prominent varicosities (large and complex vascular malformations)."</div>
                
                
                <div class="evidence-explanation">Prominent varicosities are reported as part of Proteus syndrome vascular disease.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Pulmonary embolism
                        
                        <span class="phenotype-freq">FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0002204" target="_blank">
                                Pulmonary embolism
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0002204)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/22876373" target="_blank">PMID:22876373</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"It is associated with a range of tumors, pulmonary complications, and a striking predisposition to deep vein thrombosis and pulmonary embolism."</div>
                
                
                <div class="evidence-explanation">GeneReviews identifies pulmonary embolism as a complication in Proteus syndrome.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/33987133" target="_blank">PMID:33987133</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Thus, Proteus syndrome patients are at risk of developing deep vein thrombosis and pulmonary embolism."</div>
                
                
                <div class="evidence-explanation">This case report reiterates risk of pulmonary embolism.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
            </details>
            
            <details class="phenotype-category-group" id="pheno-cat-3">
                <summary>
                    <svg class="chevron" viewBox="0 0 16 16" fill="currentColor"><path d="M6 3l5 5-5 5V3z"/></svg>
                    Eye
                    <span class="cat-count">7</span>
                </summary>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Limbal dermoid
                        
                        <span class="phenotype-freq">VERY_RARE</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0001140" target="_blank">
                                Limbal dermoid
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0001140)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/36113118" target="_blank">PMID:36113118</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Case #1 describes a 26 year old male patient followed for multiple ophthalmic anomalies: a limbal dermoid cyst, a unilateral cataract, bilateral nystagmus, severe myopia and unilateral optic nerve head drusen."</div>
                
                
                <div class="evidence-explanation">This case report documents limbal dermoid in Proteus syndrome.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Cataract
                        
                        <span class="phenotype-freq">VERY_RARE</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0000518" target="_blank">
                                Cataract
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0000518)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/36113118" target="_blank">PMID:36113118</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Case #1 describes a 26 year old male patient followed for multiple ophthalmic anomalies: a limbal dermoid cyst, a unilateral cataract, bilateral nystagmus, severe myopia and unilateral optic nerve head drusen."</div>
                
                
                <div class="evidence-explanation">The report lists unilateral cataract among ophthalmic anomalies.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Nystagmus
                        
                        <span class="phenotype-freq">VERY_RARE</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0000639" target="_blank">
                                Nystagmus
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0000639)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/36113118" target="_blank">PMID:36113118</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Case #1 describes a 26 year old male patient followed for multiple ophthalmic anomalies: a limbal dermoid cyst, a unilateral cataract, bilateral nystagmus, severe myopia and unilateral optic nerve head drusen."</div>
                
                
                <div class="evidence-explanation">Bilateral nystagmus is reported in a Proteus syndrome patient.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Myopia
                        
                        <span class="phenotype-freq">VERY_RARE</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0000545" target="_blank">
                                Myopia
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0000545)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/36113118" target="_blank">PMID:36113118</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Case #1 describes a 26 year old male patient followed for multiple ophthalmic anomalies: a limbal dermoid cyst, a unilateral cataract, bilateral nystagmus, severe myopia and unilateral optic nerve head drusen."</div>
                
                
                <div class="evidence-explanation">Severe myopia is included among the ophthalmic anomalies.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Optic disc drusen
                        
                        <span class="phenotype-freq">VERY_RARE</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0012426" target="_blank">
                                Optic disc drusen
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0012426)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/36113118" target="_blank">PMID:36113118</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Case #1 describes a 26 year old male patient followed for multiple ophthalmic anomalies: a limbal dermoid cyst, a unilateral cataract, bilateral nystagmus, severe myopia and unilateral optic nerve head drusen."</div>
                
                
                <div class="evidence-explanation">Optic nerve head drusen are reported in a Proteus syndrome patient.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Proptosis
                        
                        <span class="phenotype-freq">VERY_RARE</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0000520" target="_blank">
                                Proptosis
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0000520)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/37975355" target="_blank">PMID:37975355</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Her proptosis and vision impairment were relieved after Endoscope-Navigation system (ENS)-aided optic canal decompression."</div>
                
                
                <div class="evidence-explanation">This case report documents proptosis in Proteus syndrome.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Visual impairment
                        
                        <span class="phenotype-freq">VERY_RARE</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0000505" target="_blank">
                                Visual impairment
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0000505)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/37975355" target="_blank">PMID:37975355</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Her proptosis and vision impairment were relieved after Endoscope-Navigation system (ENS)-aided optic canal decompression."</div>
                
                
                <div class="evidence-explanation">Vision impairment is reported among ocular manifestations.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
            </details>
            
            <details class="phenotype-category-group" id="pheno-cat-4">
                <summary>
                    <svg class="chevron" viewBox="0 0 16 16" fill="currentColor"><path d="M6 3l5 5-5 5V3z"/></svg>
                    Integument
                    <span class="cat-count">2</span>
                </summary>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Epidermal nevus
                        
                        <span class="phenotype-freq">FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0010816" target="_blank">
                                Epidermal nevus
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0010816)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/33987133" target="_blank">PMID:33987133</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Proteus syndrome is an extremely rare disorder that manifests as an asymmetric, disproportionate overgrowth of any connective tissue, such as bone, fat or epidermal nevi, in a mosaic or patchy pattern."</div>
                
                
                <div class="evidence-explanation">This case report includes epidermal nevi among overgrowth manifestations.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Capillary malformation
                        
                        <span class="phenotype-freq">FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0025104" target="_blank">
                                Capillary malformation
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0025104)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/33987133" target="_blank">PMID:33987133</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Many individuals develop cutaneous capillary malformation and prominent varicosities (large and complex vascular malformations)."</div>
                
                
                <div class="evidence-explanation">This documents cutaneous capillary malformations in Proteus syndrome.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
            </details>
            
            <details class="phenotype-category-group" id="pheno-cat-5">
                <summary>
                    <svg class="chevron" viewBox="0 0 16 16" fill="currentColor"><path d="M6 3l5 5-5 5V3z"/></svg>
                    Musculoskeletal
                    <span class="cat-count">3</span>
                </summary>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Cerebriform connective tissue nevus
                        
                        <span class="phenotype-freq">FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_6000009" target="_blank">
                                Cerebriform connective tissue nevus
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:6000009)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://bioregistry.io/DOI:10.1101/mcs.a006134" target="_blank">DOI:10.1101/mcs.a006134</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"The patient has experienced sustained improvement of pain and slowed growth of bilateral plantar cerebriform connective tissue nevi."</div>
                
                
                <div class="evidence-explanation">This reports cerebriform connective tissue nevi in Proteus syndrome.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/34668833" target="_blank">PMID:34668833</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"The main histological findings are diffuse patchy overgrowth of skin and subcutaneous tissue, plantar cerebriform connective tissue nevus, and ossification defects."</div>
                
                
                <div class="evidence-explanation">The case report highlights cerebriform connective tissue nevi as a key histologic finding.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Scoliosis
                        
                        <span class="phenotype-freq">FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0002650" target="_blank">
                                Scoliosis
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0002650)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://bioregistry.io/DOI:10.1038/s41598-021-86029-0" target="_blank">DOI:10.1038/s41598-021-86029-0</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"The cardiothoracic findings of Proteus syndrome were diverse, but several were much more common and included: scoliosis from bony overgrowth (94%), pulmonary venous dilation (62%), band-like areas of lung scarring (56%), and hyperlucent lung parenchyma (50%)."</div>
                
                
                <div class="evidence-explanation">This provides cohort evidence for scoliosis due to bony overgrowth.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Lipoma
                        
                        <span class="phenotype-freq">OCCASIONAL</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0012032" target="_blank">
                                Lipoma
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0012032)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/37692275" target="_blank">PMID:37692275</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Lipomas can run in families (familial multiple lipomatosis) or be a part of genetic syndromes such as PTEN hamartoma tumor syndrome, Proteus syndrome, and Pai syndrome."</div>
                
                
                <div class="evidence-explanation">This review lists lipomas as part of Proteus syndrome presentations.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
            </details>
            
            <details class="phenotype-category-group" id="pheno-cat-6">
                <summary>
                    <svg class="chevron" viewBox="0 0 16 16" fill="currentColor"><path d="M6 3l5 5-5 5V3z"/></svg>
                    Respiratory
                    <span class="cat-count">2</span>
                </summary>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Emphysema
                        
                        <span class="phenotype-freq">OCCASIONAL</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0002097" target="_blank">
                                Emphysema
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0002097)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://bioregistry.io/DOI:10.1186/s13023-023-03013-9" target="_blank">DOI:10.1186/s13023-023-03013-9</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Individuals with Proteus syndrome can develop emphysematous and cystic changes of the lung that may lead to progressive respiratory symptoms and require surgical intervention."</div>
                
                
                <div class="evidence-explanation">This documents emphysematous lung changes in Proteus syndrome.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Multiple pulmonary cysts
                        
                        <span class="phenotype-freq">OCCASIONAL</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0005948" target="_blank">
                                Multiple pulmonary cysts
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0005948)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://bioregistry.io/DOI:10.1186/s13023-023-03013-9" target="_blank">DOI:10.1186/s13023-023-03013-9</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Individuals with Proteus syndrome can develop emphysematous and cystic changes of the lung that may lead to progressive respiratory symptoms and require surgical intervention."</div>
                
                
                <div class="evidence-explanation">This supports cystic lung changes in Proteus syndrome.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
            </details>
            
            <details class="phenotype-category-group" id="pheno-cat-7">
                <summary>
                    <svg class="chevron" viewBox="0 0 16 16" fill="currentColor"><path d="M6 3l5 5-5 5V3z"/></svg>
                    Constitutional
                    <span class="cat-count">1</span>
                </summary>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Pain
                        
                        <span class="phenotype-freq">OCCASIONAL</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0012531" target="_blank">
                                Pain
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0012531)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://bioregistry.io/DOI:10.1101/mcs.a006134" target="_blank">DOI:10.1101/mcs.a006134</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"The patient has experienced sustained improvement of pain and slowed growth of bilateral plantar cerebriform connective tissue nevi."</div>
                
                
                <div class="evidence-explanation">Pain is reported as a symptom improved with targeted therapy.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
            </details>
            
            <details class="phenotype-category-group" id="pheno-cat-8">
                <summary>
                    <svg class="chevron" viewBox="0 0 16 16" fill="currentColor"><path d="M6 3l5 5-5 5V3z"/></svg>
                    Growth
                    <span class="cat-count">2</span>
                </summary>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Overgrowth
                        
                        <span class="phenotype-freq">VERY_FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0001548" target="_blank">
                                Overgrowth
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0001548)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (4 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://bioregistry.io/DOI:10.1093/hmg/ddz116" target="_blank">DOI:10.1093/hmg/ddz116</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Common manifestations include skin and bony overgrowth, vascular malformations (VMs), cysts and benign tumors."</div>
                
                
                <div class="evidence-explanation">This highlights skin and bony overgrowth as common manifestations.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://bioregistry.io/DOI:10.1055/a-2300-7002" target="_blank">DOI:10.1055/a-2300-7002</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"It is characterized by a disproportionate, asymmetric overgrowth of all types of tissues, provoked by a somatic activating mutation in serine/threonine protein kinase 1."</div>
                
                
                <div class="evidence-explanation">This describes the characteristic disproportionate overgrowth in Proteus syndrome.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/22876373" target="_blank">PMID:22876373</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Proteus syndrome (PS) is characterized by progressive segmental or patchy overgrowth most commonly affecting the skeleton, skin, adipose, and central nervous systems."</div>
                
                
                <div class="evidence-explanation">GeneReviews describes the hallmark progressive segmental overgrowth in Proteus syndrome.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 1 more reference</div>
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Asymmetric growth
                        
                        <span class="phenotype-freq">VERY_FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0100555" target="_blank">
                                Asymmetric growth
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0100555)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://bioregistry.io/DOI:10.1055/a-2300-7002" target="_blank">DOI:10.1055/a-2300-7002</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"It is characterized by a disproportionate, asymmetric overgrowth of all types of tissues, provoked by a somatic activating mutation in serine/threonine protein kinase 1."</div>
                
                
                <div class="evidence-explanation">This explicitly describes asymmetric overgrowth as a defining feature.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/33987133" target="_blank">PMID:33987133</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Proteus syndrome is an extremely rare disorder that manifests as an asymmetric, disproportionate overgrowth of any connective tissue, such as bone, fat or epidermal nevi, in a mosaic or patchy pattern."</div>
                
                
                <div class="evidence-explanation">This case report underscores asymmetric, disproportionate overgrowth.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
            </details>
            
            <details class="phenotype-category-group" id="pheno-cat-9">
                <summary>
                    <svg class="chevron" viewBox="0 0 16 16" fill="currentColor"><path d="M6 3l5 5-5 5V3z"/></svg>
                    Neoplasm
                    <span class="cat-count">1</span>
                </summary>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Neoplasm
                        
                        <span class="phenotype-freq">OCCASIONAL</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0002664" target="_blank">
                                Neoplasm
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0002664)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (3 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://bioregistry.io/DOI:10.1136/jmg-2024-110173" target="_blank">DOI:10.1136/jmg-2024-110173</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"AKT1-related Proteus syndrome is an ultra-rare mosaic overgrowth disorder with tumour predisposition."</div>
                
                
                <div class="evidence-explanation">This systematic review establishes tumor predisposition in Proteus syndrome.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/22876373" target="_blank">PMID:22876373</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"It is associated with a range of tumors, pulmonary complications, and a striking predisposition to deep vein thrombosis and pulmonary embolism."</div>
                
                
                <div class="evidence-explanation">GeneReviews notes association with a range of tumors.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/38074478" target="_blank">PMID:38074478</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"We report a 35-year-old patient with PS, who underwent successful surgical removal of a well-differentiated SNEC obstructing his nasal cavity"</div>
                
                
                <div class="evidence-explanation">This case report documents sinonasal neuroendocrine carcinoma in Proteus syndrome.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
            </details>
            
            <script>
            (function() {
                // TOC pill click: expand target group and scroll to it
                document.querySelectorAll('.pheno-toc-pill').forEach(function(pill) {
                    pill.addEventListener('click', function() {
                        var target = document.getElementById(pill.dataset.target);
                        if (target) {
                            target.open = true;
                            target.scrollIntoView({behavior: 'smooth', block: 'start'});
                        }
                    });
                });
                // Expand/collapse all toggle
                var btn = document.getElementById('phenoToggleAll');
                if (btn) {
                    btn.addEventListener('click', function() {
                        var groups = document.querySelectorAll('.phenotype-category-group');
                        var anyOpen = Array.from(groups).some(function(g) { return g.open; });
                        groups.forEach(function(g) { g.open = !anyOpen; });
                        btn.textContent = anyOpen ? 'Expand all' : 'Collapse all';
                    });
                }
            })();
            </script>
            
        </div>
        

        <!-- Genetic Associations -->
        
        <div class="card" id="genetic">
            <div class="card-header">
                <div class="card-icon" style="background: #dbeafe; color: #2563eb;">🧬</div>
                <h2 class="card-title">Genetic Associations</h2>
                <span class="card-count">1</span>
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    AKT1
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Causative)</span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://bioregistry.io/DOI:10.1038/srep17162" target="_blank">DOI:10.1038/srep17162</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"A somatic activating mutation in AKT1, c.49G&gt;A, pGlu17Lys, that results in elevated AKT signaling in mutation-positive cells, is responsible for the mosaic overgrowth condition, Proteus syndrome."</div>
                
                
                <div class="evidence-explanation">This identifies the causative somatic AKT1 variant.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://bioregistry.io/DOI:10.1093/hmg/ddz116" target="_blank">DOI:10.1093/hmg/ddz116</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Proteus syndrome is a mosaic, progressive overgrowth disorder caused by a somatic activating variant c.49G &gt; A p.(E17K) in AKT1."</div>
                
                
                <div class="evidence-explanation">This independently confirms the AKT1 p.E17K mosaic variant as the cause.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Treatments -->
        
        <div class="card" id="treatments">
            <div class="card-header">
                <div class="card-icon" style="background: #ede9fe; color: #7c3aed;">💊</div>
                <h2 class="card-title">Treatments</h2>
                <span class="card-count">2</span>
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    AKT inhibitor (miransertib/ARQ 092)
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000058" target="_blank">
                            MAXO:0000058
                        </a>
                    </span>
                    
                </div>
                
                
                <div class="item-desc">Allosteric pan-AKT inhibitor used to suppress AKT signaling and evaluated clinically for symptom and overgrowth control in Proteus syndrome.</div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://bioregistry.io/DOI:10.1038/srep17162" target="_blank">DOI:10.1038/srep17162</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"ARQ 092 reduced phosphorylation of AKT and downstream targets of AKT in a concentration-dependent manner in as little as two hours."</div>
                
                
                <div class="evidence-explanation">This shows AKT pathway suppression by ARQ 092 in Proteus syndrome samples.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://bioregistry.io/DOI:10.1101/mcs.a006134" target="_blank">DOI:10.1101/mcs.a006134</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"The patient has experienced sustained improvement of pain and slowed growth of bilateral plantar cerebriform connective tissue nevi."</div>
                
                
                <div class="evidence-explanation">This case report describes clinical benefit with miransertib (ARQ 092).</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Surgical intervention
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000004" target="_blank">
                            MAXO:0000004
                        </a>
                    </span>
                    
                </div>
                
                
                <div class="item-desc">Surgical debulking or corrective procedures used to manage focal overgrowth and deformity.</div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://bioregistry.io/DOI:10.1055/a-2300-7002" target="_blank">DOI:10.1055/a-2300-7002</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"We report a case of PS in a two-year-old female patient with the following clinical features: unilateral overgrowth of connective tissue in the right buttock and right foot, where multiple surgeries were performed to achieve a desirable aesthetic outcome and ensure psychological comfort of the..."</div>
                
                
                <div class="evidence-explanation">This case report documents surgical intervention for overgrowth management.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Environmental Factors -->
        

        <!-- Biochemical Markers -->
        

        <!-- Differential Diagnoses -->
        
        <div class="card" id="differentials">
            <div class="card-header">
                <div class="card-icon" style="background: #fef2f2; color: #dc2626;">🔀</div>
                <h2 class="card-title">Differential Diagnoses</h2>
                <span class="card-count">6</span>
            </div>
            <p style="margin-bottom: 16px; font-size: 0.95rem; color: var(--text-muted);">
                Conditions with similar clinical presentations that must be differentiated from Proteus syndrome:
            </p>
            
            <div class="item-box differential-box">
                <div class="item-name">
                    Klippel-Trenaunay-Weber syndrome
                    
                </div>
                
                <div class="differential-similarities">
                    <strong>Overlapping Features</strong>
                    Overgrowth with vascular malformations can resemble Proteus syndrome and requires clinical and radiologic differentiation.

                </div>
                
                
                <div class="differential-distinctions">
                    <strong>Distinguishing Features</strong>
                    
                    <ul>
                        
                        <li>Capillary/venous malformations with limb hypertrophy and port-wine stains</li>
                        
                        <li>Typically lacks cerebriform connective tissue nevi</li>
                        
                    </ul>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/25009745" target="_blank">PMID:25009745</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"In the current review, four overgrowth syndromes were characterized (Proteus syndrome, Klippel-Trenaunay-Weber syndrome, Madelung&#39;s disease, and neurofibromatosis type I) and illustrated using cases from our institution."</div>
                
                
                <div class="evidence-explanation">This review explicitly lists Klippel-Trenaunay-Weber syndrome alongside Proteus syndrome in differential evaluation of overgrowth syndromes.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box differential-box">
                <div class="item-name">
                    Madelung&#39;s disease (multiple symmetric lipomatosis)
                    
                    <span class="phenotype-id">
                        <a href="http://purl.obolibrary.org/obo/MONDO_0007908" target="_blank">
                            MONDO:0007908
                        </a>
                    </span>
                    
                </div>
                
                <div class="differential-similarities">
                    <strong>Overlapping Features</strong>
                    Symmetric lipomatous overgrowth can resemble Proteus syndrome and should be differentiated based on distribution and accompanying malformations.

                </div>
                
                
                <div class="differential-distinctions">
                    <strong>Distinguishing Features</strong>
                    
                    <ul>
                        
                        <li>Symmetric lipomatous masses rather than mosaic, segmental overgrowth</li>
                        
                        <li>Absence of cerebriform connective tissue nevi</li>
                        
                    </ul>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/25009745" target="_blank">PMID:25009745</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"In the current review, four overgrowth syndromes were characterized (Proteus syndrome, Klippel-Trenaunay-Weber syndrome, Madelung&#39;s disease, and neurofibromatosis type I) and illustrated using cases from our institution."</div>
                
                
                <div class="evidence-explanation">This review includes Madelung&#39;s disease among Proteus syndrome differentials.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box differential-box">
                <div class="item-name">
                    Neurofibromatosis type I
                    
                    <span class="phenotype-id">
                        <a href="http://purl.obolibrary.org/obo/MONDO_0018975" target="_blank">
                            MONDO:0018975
                        </a>
                    </span>
                    
                </div>
                
                <div class="differential-similarities">
                    <strong>Overlapping Features</strong>
                    Neurocutaneous overgrowth and benign tumors can overlap with Proteus syndrome, but NF1 has distinct diagnostic features.

                </div>
                
                
                <div class="differential-distinctions">
                    <strong>Distinguishing Features</strong>
                    
                    <ul>
                        
                        <li>Cafe-au-lait macules and neurofibromas</li>
                        
                        <li>Lisch nodules and NF1 pathogenic variants</li>
                        
                    </ul>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/25009745" target="_blank">PMID:25009745</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"In the current review, four overgrowth syndromes were characterized (Proteus syndrome, Klippel-Trenaunay-Weber syndrome, Madelung&#39;s disease, and neurofibromatosis type I) and illustrated using cases from our institution."</div>
                
                
                <div class="evidence-explanation">This review includes neurofibromatosis type I among overgrowth syndromes that overlap with Proteus syndrome.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box differential-box">
                <div class="item-name">
                    CLOVES syndrome
                    
                    <span class="phenotype-id">
                        <a href="http://purl.obolibrary.org/obo/MONDO_0013038" target="_blank">
                            MONDO:0013038
                        </a>
                    </span>
                    
                </div>
                
                <div class="differential-similarities">
                    <strong>Overlapping Features</strong>
                    Segmental overgrowth with complex vascular and soft tissue malformations can overlap with Proteus syndrome presentations.

                </div>
                
                
                <div class="differential-distinctions">
                    <strong>Distinguishing Features</strong>
                    
                    <ul>
                        
                        <li>Typically congenital, with lipomatous truncal overgrowth and vascular malformations</li>
                        
                        <li>PIK3CA-related overgrowth rather than AKT1 mosaic variant</li>
                        
                    </ul>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/34668833" target="_blank">PMID:34668833</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Discussion: CLOVES syndrome, neurofibromatosis 1 or PTEN hamartoma tumor syndrome are partially superimposable entities to Proteus syndrome and may generate diagnostic doubt."</div>
                
                
                <div class="evidence-explanation">This case report lists CLOVES among overlapping entities in differential diagnosis.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box differential-box">
                <div class="item-name">
                    PTEN hamartoma tumor syndrome
                    
                    <span class="phenotype-id">
                        <a href="http://purl.obolibrary.org/obo/MONDO_0017623" target="_blank">
                            MONDO:0017623
                        </a>
                    </span>
                    
                </div>
                
                <div class="differential-similarities">
                    <strong>Overlapping Features</strong>
                    PTEN-related overgrowth and hamartomatous features can mimic Proteus syndrome, requiring molecular differentiation.

                </div>
                
                
                <div class="differential-distinctions">
                    <strong>Distinguishing Features</strong>
                    
                    <ul>
                        
                        <li>Germline PTEN variants with systemic hamartomas and cancer predisposition</li>
                        
                        <li>Macrocephaly and mucocutaneous findings typical of PHTS</li>
                        
                    </ul>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (3 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/34668833" target="_blank">PMID:34668833</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Discussion: CLOVES syndrome, neurofibromatosis 1 or PTEN hamartoma tumor syndrome are partially superimposable entities to Proteus syndrome and may generate diagnostic doubt."</div>
                
                
                <div class="evidence-explanation">This case report highlights PTEN hamartoma tumor syndrome as a differential.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/20301661" target="_blank">PMID:20301661</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"The PTEN hamartoma tumor syndrome (PHTS) includes Cowden syndrome (CS), Bannayan-Riley-Ruvalcaba syndrome (BRRS), PTEN-related Proteus syndrome (PS), and PTEN-related Proteus-like syndrome."</div>
                
                
                <div class="evidence-explanation">GeneReviews links PTEN hamartoma tumor syndrome to PTEN-related Proteus/Proteus-like presentations.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/40058215" target="_blank">PMID:40058215</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"PTEN hamartomas cause a variety of conditions, including Cowden syndrome, Bannayan-Riley-Ruvalcaba syndrome, PTEN-related Proteus syndrome, and Proteus-like syndrome."</div>
                
                
                <div class="evidence-explanation">This case report reiterates PTEN-related Proteus syndromes within the PTEN hamartoma spectrum.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box differential-box">
                <div class="item-name">
                    Bannayan-Riley-Ruvalcaba syndrome
                    
                    <span class="phenotype-id">
                        <a href="http://purl.obolibrary.org/obo/MONDO_0007924" target="_blank">
                            MONDO:0007924
                        </a>
                    </span>
                    
                </div>
                
                <div class="differential-similarities">
                    <strong>Overlapping Features</strong>
                    PTEN-related overgrowth syndrome that can overlap with Proteus-like features and should be distinguished by germline PTEN findings and classic mucocutaneous/hamartomatous manifestations.

                </div>
                
                
                <div class="differential-distinctions">
                    <strong>Distinguishing Features</strong>
                    
                    <ul>
                        
                        <li>Macrocephaly with hamartomatous polyposis and lipomas</li>
                        
                        <li>Germline PTEN variants with systemic findings</li>
                        
                    </ul>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/20301661" target="_blank">PMID:20301661</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"The PTEN hamartoma tumor syndrome (PHTS) includes Cowden syndrome (CS), Bannayan-Riley-Ruvalcaba syndrome (BRRS), PTEN-related Proteus syndrome (PS), and PTEN-related Proteus-like syndrome."</div>
                
                
                <div class="evidence-explanation">GeneReviews includes BRRS within the PTEN hamartoma tumor syndrome spectrum relevant to Proteus differentials.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Datasets -->
        

        <!-- Clinical Trials -->
        
        <div class="card" id="trials">
            <div class="card-header">
                <div class="card-icon" style="background: #f5f3ff; color: #a855f7;">🔬</div>
                <h2 class="card-title">Clinical Trials</h2>
                <span class="card-count">6</span>
            </div>
            
            <div class="item-box clinical-trial-box">
                <div class="item-name">
                    NCT04316546
                    
                    <span class="tag tag-phase">PHASE_II</span>
                    
                    
                    <span class="tag tag-status">RECRUITING</span>
                    
                </div>
                
                <div class="item-desc">Multi-cohort Phase 2 dose-escalation study of miransertib (MK-7075) in Proteus syndrome.</div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://clinicaltrials.gov/study/NCT04316546" target="_blank">clinicaltrials:NCT04316546</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"To learn if miransertib is a safe and effective treatment for Proteus syndrome."</div>
                
                
                <div class="evidence-explanation">The trial objective confirms evaluation of miransertib for Proteus syndrome.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box clinical-trial-box">
                <div class="item-name">
                    NCT02594215
                    
                    <span class="tag tag-phase">PHASE_I</span>
                    
                    
                    <span class="tag tag-status">COMPLETED</span>
                    
                </div>
                
                <div class="item-desc">Dose-finding study of MK-7075 (miransertib) in children and adults with Proteus syndrome.</div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://clinicaltrials.gov/study/NCT02594215" target="_blank">clinicaltrials:NCT02594215</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"To determine the safety, tolerability, and recommended dose of MK-7075 in people with PS."</div>
                
                
                <div class="evidence-explanation">The trial objective defines dose-finding and safety assessment in Proteus syndrome.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box clinical-trial-box">
                <div class="item-name">
                    NCT03094832
                    
                    <span class="tag tag-phase">PHASE_I</span>
                    
                    
                    <span class="tag tag-status">TERMINATED</span>
                    
                </div>
                
                <div class="item-desc">Phase 1/2 open-label study of oral miransertib (MK-7075) in PROS and Proteus syndrome (MOSAIC).</div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://clinicaltrials.gov/study/NCT03094832" target="_blank">clinicaltrials:NCT03094832</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"This is an open label, Phase 1/2 study of oral miransertib (MK-7075) administered to participants at least 2 years of age with phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha (PIK3CA)-related Overgrowth Spectrum (PROS) and Proteus Syndrome (PS) (MOSAIC)."</div>
                
                
                <div class="evidence-explanation">The trial summary describes the Phase 1/2 MOSAIC study including Proteus syndrome.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box clinical-trial-box">
                <div class="item-name">
                    NCT04980872
                    
                    <span class="tag tag-phase">PHASE_II</span>
                    
                    
                    <span class="tag tag-status">ACTIVE_NOT_RECRUITING</span>
                    
                </div>
                
                <div class="item-desc">Extension study evaluating safety/tolerability of oral miransertib in PROS or Proteus syndrome.</div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://clinicaltrials.gov/study/NCT04980872" target="_blank">clinicaltrials:NCT04980872</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"This is a study of the safety and tolerability of oral miransertib (MK-7075) administered to participants at least 2 years of age with phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA)-related overgrowth spectrum (PROS) or Proteus Syndrome (PS)."</div>
                
                
                <div class="evidence-explanation">The study summary states the safety/tolerability focus for PROS or Proteus syndrome participants.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box clinical-trial-box">
                <div class="item-name">
                    NCT03317366
                    
                    <span class="tag tag-phase">NOT_APPLICABLE</span>
                    
                    
                    <span class="tag tag-status">UNKNOWN</span>
                    
                </div>
                
                <div class="item-desc">Expanded access for ARQ 092 (miransertib) in overgrowth diseases or vascular anomalies with PI3K/AKT alterations.</div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://clinicaltrials.gov/study/NCT03317366" target="_blank">clinicaltrials:NCT03317366</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"ARQ 092 is being investigated for patients with overgrowth diseases and/or vascular anomalies with genetic alterations of the PI3K/AKT pathway and may be available for patients who are ineligible for an ongoing ARQ 092 clinical trial or have other considerations that prevent access to ARQ 092..."</div>
                
                
                <div class="evidence-explanation">The summary describes expanded access for PI3K/AKT-pathway overgrowth disorders including Proteus syndrome.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box clinical-trial-box">
                <div class="item-name">
                    NCT00001403
                    
                    <span class="tag tag-phase">NOT_APPLICABLE</span>
                    
                    
                    <span class="tag tag-status">RECRUITING</span>
                    
                </div>
                
                <div class="item-desc">Natural history study of Proteus syndrome and related congenital overgrowth disorders.</div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://clinicaltrials.gov/study/NCT00001403" target="_blank">clinicaltrials:NCT00001403</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"This study will examine rare congenital disorders that involve malformations and abnormal growth. It will focus on patients with Proteus syndrome, whose physical features are characterized by overgrowth, benign tumors of fatty tissue or blood vessels, asymmetric arms or legs, and large feet with..."</div>
                
                
                <div class="evidence-explanation">The study description states a natural history focus on Proteus syndrome.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- YAML Source -->
        <div class="card">
            <div class="card-header" style="cursor: pointer;" onclick="toggleYaml()">
                <div class="card-icon" style="background: #f1f5f9; color: #475569;">{ }</div>
                <h2 class="card-title">Source YAML</h2>
                <span class="card-count" id="yamlToggleText">click to show</span>
            </div>
            <div class="yaml-content" id="yamlContent">
                <pre class="yaml-preview">name: Proteus syndrome
creation_date: &#39;2026-01-27T17:46:29Z&#39;
updated_date: &#39;2026-01-28T17:04:03Z&#39;
category: Mendelian
parents: []
disease_term:
  preferred_term: Proteus syndrome
  term:
    id: MONDO:0008318
    label: Proteus syndrome
prevalence:
- population: Reported cases
  percentage: Rare
  notes: Approximately 250 cases documented in the literature over the past four decades.
  evidence:
  - reference: DOI:10.1186/s13023-023-03013-9
    supports: SUPPORT
    snippet: &#34;Proteus syndrome is an ultra-rare mosaic overgrowth disorder.&#34;
    explanation: This statement characterizes Proteus syndrome as ultra-rare.
  - reference: DOI:10.1055/a-2300-7002
    supports: SUPPORT
    snippet: &#34;Proteus syndrome (PS) is an exceptionally uncommon genetic disorder that has been documented in only approximately 250 cases in the literature spanning the past four decades.&#34;
    explanation: This provides a literature-based estimate of reported case counts.
- population: Live births
  percentage: 0.0001
  notes: Estimated prevalence is less than 1 per 1,000,000 live births.
  evidence:
  - reference: PMID:33987133
    supports: SUPPORT
    snippet: &#34;It has an estimated prevalence of less than 1/1,000,000 live births.&#34;
    explanation: This case report provides a population prevalence estimate for Proteus syndrome.
epidemiology:
- name: Sex distribution in imaging cohort
  description: Male predominance reported in a cardiothoracic imaging cohort.
  unit: cases
  notes: In a cohort of 38 imaged individuals, 23 were men.
  evidence:
  - reference: DOI:10.1038/s41598-021-86029-0
    supports: SUPPORT
    snippet: &#34;Of 53 individuals with a confirmed diagnosis of Proteus syndrome at our institution from 10/2001 to 10/2019, 38 individuals (men, n = 23; average age = 24 years) underwent cardiothoracic imaging&#34;
    explanation: This cohort reports a male-predominant sex distribution among imaged individuals.
- name: Sex distribution in longitudinal cohort
  description: Male predominance reported in a 64-patient natural history cohort.
  unit: cases
  notes: 36 males and 28 females in the cohort.
  evidence:
  - reference: PMID:28661492
    supports: SUPPORT
    snippet: &#34;There were 64 patients with Proteus syndrome identified in this study, 28 (43.8%) were female and 36 were male (56.3%).&#34;
    explanation: The longitudinal cohort reports a modest male predominance.
- name: Age in imaging cohort
  description: Average age reported for the cardiothoracic imaging cohort.
  mean_range: 24 years
  unit: years
  evidence:
  - reference: DOI:10.1038/s41598-021-86029-0
    supports: SUPPORT
    snippet: &#34;Of 53 individuals with a confirmed diagnosis of Proteus syndrome at our institution from 10/2001 to 10/2019, 38 individuals (men, n = 23; average age = 24 years) underwent cardiothoracic imaging&#34;
    explanation: The imaging cohort reports an average age of 24 years.
- name: Age at diagnosis
  description: Median age at diagnosis in a natural history cohort.
  mean_range: 19 months
  unit: months
  evidence:
  - reference: PMID:28661492
    supports: SUPPORT
    snippet: &#34;The median age of diagnosis was 19 months.&#34;
    explanation: The cohort analysis reports a median diagnosis age of 19 months.
pathophysiology:
- name: Somatic AKT1 p.E17K activation in mosaic cell clones
  description: &gt;
    Proteus syndrome is caused by a post-zygotic activating AKT1 p.E17K
    variant present in a mosaic subset of cells.
  evidence:
  - reference: DOI:10.1038/srep17162
    supports: SUPPORT
    snippet: &#34;A somatic activating mutation in AKT1, c.49G&gt;A, pGlu17Lys, that results in elevated AKT signaling in mutation-positive cells, is responsible for the mosaic overgrowth condition, Proteus syndrome.&#34;
    explanation: This establishes mosaic, somatic AKT1 p.E17K activation in Proteus syndrome.
- name: Elevated PI3K/AKT signaling in AKT1-mutant cells
  description: &gt;
    AKT1 p.E17K drives increased PI3K/AKT pathway activity in mutation-positive
    cells, promoting downstream overgrowth signals.
  biological_processes:
  - preferred_term: phosphatidylinositol 3-kinase/protein kinase B signal transduction
    term:
      id: GO:0043491
      label: phosphatidylinositol 3-kinase/protein kinase B signal transduction
    modifier: INCREASED
  evidence:
  - reference: DOI:10.1038/srep17162
    supports: SUPPORT
    snippet: &#34;A somatic activating mutation in AKT1, c.49G&gt;A, pGlu17Lys, that results in elevated AKT signaling in mutation-positive cells, is responsible for the mosaic overgrowth condition, Proteus syndrome.&#34;
    explanation: This directly links AKT1 activation to elevated AKT signaling in mutation-positive cells.
- name: Increased pAKT signaling in AKT1-mutant lesion cells
  description: &gt;
    Lesion cells harboring AKT1 p.E17K show increased pAKT signaling within
    hyperplastic regions.
  biological_processes:
  - preferred_term: protein phosphorylation
    term:
      id: GO:0006468
      label: protein phosphorylation
    modifier: INCREASED
  evidence:
  - reference: DOI:10.1093/hmg/ddz116
    supports: SUPPORT
    snippet: &#34;Identification of variant-positive cells by green fluorescent protein (GFP) staining in chimeric Proteus syndrome mice showed that in some lesions, hyperplastic cells were predominantly GFP/Akt1E17K-positive and showed increased pAKT signal compared to GFP-negative cells.&#34;
    explanation: This demonstrates increased pAKT signaling in mutant clones within lesions.
- name: Non-cell-autonomous pAKT activation in adjacent cells
  description: &gt;
    AKT1-mutant clones can induce increased pAKT signaling in nearby
    mutation-negative cells, consistent with non-cell-autonomous lesion
    propagation.
  biological_processes:
  - preferred_term: cell-cell signaling
    term:
      id: GO:0007267
      label: cell-cell signaling
    modifier: INCREASED
  evidence:
  - reference: DOI:10.1093/hmg/ddz116
    supports: SUPPORT
    snippet: &#34;However, hyperplastic mammary epithelium was a mixture of GFP/Akt1E17K-positive and negative cells with some GFP/Akt1E17K-negative cells also having increased pAKT signal suggesting that the variant-positive cells can induce lesion formation in a non-cell autonomous manner.&#34;
    explanation: This provides evidence for non-cell-autonomous effects in lesion formation.
- name: AKT overactivation induces excessive vasculogenesis
  description: &gt;
    AKT1 activation increases vascular connectivity and promotes
    vasculogenesis with enhanced vascular sprouting.
  cell_types:
  - preferred_term: endothelial cell
    term:
      id: CL:0000115
      label: endothelial cell
  biological_processes:
  - preferred_term: vasculogenesis
    term:
      id: GO:0001570
      label: vasculogenesis
    modifier: INCREASED
  - preferred_term: angiogenesis
    term:
      id: GO:0001525
      label: angiogenesis
    modifier: INCREASED
  evidence:
  - reference: DOI:10.1101/2024.01.26.577324
    supports: SUPPORT
    snippet: &#34;Our findings revealed that AKT overactivation in these organoids resulted in smaller sizes yet increased vascular connectivity, although with less stable connections.&#34;
    explanation: AKT overactivation increases vascular connectivity in organoid vasculature.
  - reference: DOI:10.1101/2024.01.26.577324
    supports: SUPPORT
    snippet: &#34;This could be due to the significant vasculogenesis induced by AKT overactivation.&#34;
    explanation: The study explicitly links AKT overactivation to increased vasculogenesis.
- name: Mural cell dysfunction destabilizes vascular connections
  description: &gt;
    AKT-driven vascular malformations include dysfunctional PDGFRβ+ mural
    cells with impaired matrix secretion, contributing to unstable vessel
    connections.
  cell_types:
  - preferred_term: pericyte
    term:
      id: CL:0000669
      label: pericyte
  biological_processes:
  - preferred_term: extracellular matrix organization
    term:
      id: GO:0030198
      label: extracellular matrix organization
    modifier: DECREASED
  evidence:
  - reference: DOI:10.1101/2024.01.26.577324
    supports: SUPPORT
    snippet: &#34;Our findings revealed that AKT overactivation in these organoids resulted in smaller sizes yet increased vascular connectivity, although with less stable connections.&#34;
    explanation: AKT overactivation is linked to unstable vascular connections.
  - reference: DOI:10.1101/2024.01.26.577324
    supports: SUPPORT
    snippet: &#34;Additionally, a notable increase in dysfunctional PDGFRβ + mural cells, impaired in matrix secretion, was observed in these AKT-overactivated organoids.&#34;
    explanation: This supports mural cell dysfunction as part of the vascular phenotype.
phenotypes:
- name: Overgrowth
  category: Musculoskeletal
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Overgrowth
    term:
      id: HP:0001548
      label: Overgrowth
  evidence:
  - reference: DOI:10.1093/hmg/ddz116
    supports: SUPPORT
    snippet: &#34;Common manifestations include skin and bony overgrowth, vascular malformations (VMs), cysts and benign tumors.&#34;
    explanation: This highlights skin and bony overgrowth as common manifestations.
  - reference: DOI:10.1055/a-2300-7002
    supports: SUPPORT
    snippet: &#34;It is characterized by a disproportionate, asymmetric overgrowth of all types of tissues, provoked by a somatic activating mutation in serine/threonine protein kinase 1.&#34;
    explanation: This describes the characteristic disproportionate overgrowth in Proteus syndrome.
  - reference: PMID:22876373
    supports: SUPPORT
    snippet: &#34;Proteus syndrome (PS) is characterized by progressive segmental or patchy overgrowth most commonly affecting the skeleton, skin, adipose, and central nervous systems.&#34;
    explanation: GeneReviews describes the hallmark progressive segmental overgrowth in Proteus syndrome.
  - reference: PMID:33987133
    supports: SUPPORT
    snippet: &#34;Proteus syndrome is an extremely rare disorder that manifests as an asymmetric, disproportionate overgrowth of any connective tissue, such as bone, fat or epidermal nevi, in a mosaic or patchy pattern.&#34;
    explanation: This case report emphasizes disproportionate connective tissue overgrowth.
- name: Asymmetric growth
  category: Growth
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Asymmetric growth
    term:
      id: HP:0100555
      label: Asymmetric growth
  evidence:
  - reference: DOI:10.1055/a-2300-7002
    supports: SUPPORT
    snippet: &#34;It is characterized by a disproportionate, asymmetric overgrowth of all types of tissues, provoked by a somatic activating mutation in serine/threonine protein kinase 1.&#34;
    explanation: This explicitly describes asymmetric overgrowth as a defining feature.
  - reference: PMID:33987133
    supports: SUPPORT
    snippet: &#34;Proteus syndrome is an extremely rare disorder that manifests as an asymmetric, disproportionate overgrowth of any connective tissue, such as bone, fat or epidermal nevi, in a mosaic or patchy pattern.&#34;
    explanation: This case report underscores asymmetric, disproportionate overgrowth.
- name: Venous malformation
  category: Cardiovascular
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Venous malformation
    term:
      id: HP:0012721
      label: Venous malformation
  evidence:
  - reference: DOI:10.1093/hmg/ddz116
    supports: SUPPORT
    snippet: &#34;Common manifestations include skin and bony overgrowth, vascular malformations (VMs), cysts and benign tumors.&#34;
    explanation: This lists vascular malformations among common Proteus syndrome manifestations.
  - reference: PMID:33987133
    supports: SUPPORT
    snippet: &#34;Many individuals develop cutaneous capillary malformation and prominent varicosities (large and complex vascular malformations).&#34;
    explanation: This documents vascular malformations with prominent varicosities in Proteus syndrome.
- name: Cerebriform connective tissue nevus
  category: Dermatologic
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Cerebriform connective tissue nevus
    term:
      id: HP:6000009
      label: Cerebriform connective tissue nevus
  evidence:
  - reference: DOI:10.1101/mcs.a006134
    supports: SUPPORT
    snippet: &#34;The patient has experienced sustained improvement of pain and slowed growth of bilateral plantar cerebriform connective tissue nevi.&#34;
    explanation: This reports cerebriform connective tissue nevi in Proteus syndrome.
  - reference: PMID:34668833
    supports: SUPPORT
    snippet: &#34;The main histological findings are diffuse patchy overgrowth of skin and subcutaneous tissue, plantar cerebriform connective tissue nevus, and ossification defects.&#34;
    explanation: The case report highlights cerebriform connective tissue nevi as a key histologic finding.
- name: Epidermal nevus
  category: Dermatologic
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Epidermal nevus
    term:
      id: HP:0010816
      label: Epidermal nevus
  evidence:
  - reference: PMID:33987133
    supports: SUPPORT
    snippet: &#34;Proteus syndrome is an extremely rare disorder that manifests as an asymmetric, disproportionate overgrowth of any connective tissue, such as bone, fat or epidermal nevi, in a mosaic or patchy pattern.&#34;
    explanation: This case report includes epidermal nevi among overgrowth manifestations.
- name: Capillary malformation
  category: Cardiovascular
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Capillary malformation
    term:
      id: HP:0025104
      label: Capillary malformation
  evidence:
  - reference: PMID:33987133
    supports: SUPPORT
    snippet: &#34;Many individuals develop cutaneous capillary malformation and prominent varicosities (large and complex vascular malformations).&#34;
    explanation: This documents cutaneous capillary malformations in Proteus syndrome.
- name: Varicose veins
  category: Cardiovascular
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Varicose veins
    term:
      id: HP:0002619
      label: Varicose veins
  evidence:
  - reference: PMID:33987133
    supports: SUPPORT
    snippet: &#34;Many individuals develop cutaneous capillary malformation and prominent varicosities (large and complex vascular malformations).&#34;
    explanation: Prominent varicosities are reported as part of Proteus syndrome vascular disease.
- name: Pain
  category: Neurologic
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Pain
    term:
      id: HP:0012531
      label: Pain
  evidence:
  - reference: DOI:10.1101/mcs.a006134
    supports: SUPPORT
    snippet: &#34;The patient has experienced sustained improvement of pain and slowed growth of bilateral plantar cerebriform connective tissue nevi.&#34;
    explanation: Pain is reported as a symptom improved with targeted therapy.
- name: Scoliosis
  category: Musculoskeletal
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Scoliosis
    term:
      id: HP:0002650
      label: Scoliosis
  evidence:
  - reference: DOI:10.1038/s41598-021-86029-0
    supports: SUPPORT
    snippet: &#34;The cardiothoracic findings of Proteus syndrome were diverse, but several were much more common and included: scoliosis from bony overgrowth (94%), pulmonary venous dilation (62%), band-like areas of lung scarring (56%), and hyperlucent lung parenchyma (50%).&#34;
    explanation: This provides cohort evidence for scoliosis due to bony overgrowth.
- name: Emphysema
  category: Respiratory
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Emphysema
    term:
      id: HP:0002097
      label: Emphysema
  evidence:
  - reference: DOI:10.1186/s13023-023-03013-9
    supports: SUPPORT
    snippet: &#34;Individuals with Proteus syndrome can develop emphysematous and cystic changes of the lung that may lead to progressive respiratory symptoms and require surgical intervention.&#34;
    explanation: This documents emphysematous lung changes in Proteus syndrome.
- name: Multiple pulmonary cysts
  category: Respiratory
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Multiple pulmonary cysts
    term:
      id: HP:0005948
      label: Multiple pulmonary cysts
  evidence:
  - reference: DOI:10.1186/s13023-023-03013-9
    supports: SUPPORT
    snippet: &#34;Individuals with Proteus syndrome can develop emphysematous and cystic changes of the lung that may lead to progressive respiratory symptoms and require surgical intervention.&#34;
    explanation: This supports cystic lung changes in Proteus syndrome.
- name: Deep vein thrombosis
  category: Cardiovascular
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Deep venous thrombosis
    term:
      id: HP:0002625
      label: Deep venous thrombosis
  evidence:
  - reference: PMID:22876373
    supports: SUPPORT
    snippet: &#34;It is associated with a range of tumors, pulmonary complications, and a striking predisposition to deep vein thrombosis and pulmonary embolism.&#34;
    explanation: GeneReviews documents a predisposition to deep vein thrombosis in Proteus syndrome.
  - reference: PMID:33987133
    supports: SUPPORT
    snippet: &#34;Thus, Proteus syndrome patients are at risk of developing deep vein thrombosis and pulmonary embolism.&#34;
    explanation: This case report confirms thrombotic risk in Proteus syndrome.
- name: Pulmonary embolism
  category: Cardiovascular
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Pulmonary embolism
    term:
      id: HP:0002204
      label: Pulmonary embolism
  evidence:
  - reference: PMID:22876373
    supports: SUPPORT
    snippet: &#34;It is associated with a range of tumors, pulmonary complications, and a striking predisposition to deep vein thrombosis and pulmonary embolism.&#34;
    explanation: GeneReviews identifies pulmonary embolism as a complication in Proteus syndrome.
  - reference: PMID:33987133
    supports: SUPPORT
    snippet: &#34;Thus, Proteus syndrome patients are at risk of developing deep vein thrombosis and pulmonary embolism.&#34;
    explanation: This case report reiterates risk of pulmonary embolism.
- name: Lipoma
  category: Dermatologic
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Lipoma
    term:
      id: HP:0012032
      label: Lipoma
  evidence:
  - reference: PMID:37692275
    supports: SUPPORT
    snippet: &#34;Lipomas can run in families (familial multiple lipomatosis) or be a part of genetic syndromes such as PTEN hamartoma tumor syndrome, Proteus syndrome, and Pai syndrome.&#34;
    explanation: This review lists lipomas as part of Proteus syndrome presentations.
- name: Limbal dermoid
  category: Ophthalmologic
  frequency: VERY_RARE
  phenotype_term:
    preferred_term: Limbal dermoid
    term:
      id: HP:0001140
      label: Limbal dermoid
  evidence:
  - reference: PMID:36113118
    supports: SUPPORT
    snippet: &#34;Case #1 describes a 26 year old male patient followed for multiple ophthalmic anomalies: a limbal dermoid cyst, a unilateral cataract, bilateral nystagmus, severe myopia and unilateral optic nerve head drusen.&#34;
    explanation: This case report documents limbal dermoid in Proteus syndrome.
- name: Cataract
  category: Ophthalmologic
  frequency: VERY_RARE
  phenotype_term:
    preferred_term: Cataract
    term:
      id: HP:0000518
      label: Cataract
  evidence:
  - reference: PMID:36113118
    supports: SUPPORT
    snippet: &#34;Case #1 describes a 26 year old male patient followed for multiple ophthalmic anomalies: a limbal dermoid cyst, a unilateral cataract, bilateral nystagmus, severe myopia and unilateral optic nerve head drusen.&#34;
    explanation: The report lists unilateral cataract among ophthalmic anomalies.
- name: Nystagmus
  category: Ophthalmologic
  frequency: VERY_RARE
  phenotype_term:
    preferred_term: Nystagmus
    term:
      id: HP:0000639
      label: Nystagmus
  evidence:
  - reference: PMID:36113118
    supports: SUPPORT
    snippet: &#34;Case #1 describes a 26 year old male patient followed for multiple ophthalmic anomalies: a limbal dermoid cyst, a unilateral cataract, bilateral nystagmus, severe myopia and unilateral optic nerve head drusen.&#34;
    explanation: Bilateral nystagmus is reported in a Proteus syndrome patient.
- name: Myopia
  category: Ophthalmologic
  frequency: VERY_RARE
  phenotype_term:
    preferred_term: Myopia
    term:
      id: HP:0000545
      label: Myopia
  evidence:
  - reference: PMID:36113118
    supports: SUPPORT
    snippet: &#34;Case #1 describes a 26 year old male patient followed for multiple ophthalmic anomalies: a limbal dermoid cyst, a unilateral cataract, bilateral nystagmus, severe myopia and unilateral optic nerve head drusen.&#34;
    explanation: Severe myopia is included among the ophthalmic anomalies.
- name: Optic disc drusen
  category: Ophthalmologic
  frequency: VERY_RARE
  phenotype_term:
    preferred_term: Optic disc drusen
    term:
      id: HP:0012426
      label: Optic disc drusen
  evidence:
  - reference: PMID:36113118
    supports: SUPPORT
    snippet: &#34;Case #1 describes a 26 year old male patient followed for multiple ophthalmic anomalies: a limbal dermoid cyst, a unilateral cataract, bilateral nystagmus, severe myopia and unilateral optic nerve head drusen.&#34;
    explanation: Optic nerve head drusen are reported in a Proteus syndrome patient.
- name: Proptosis
  category: Ophthalmologic
  frequency: VERY_RARE
  phenotype_term:
    preferred_term: Proptosis
    term:
      id: HP:0000520
      label: Proptosis
  evidence:
  - reference: PMID:37975355
    supports: SUPPORT
    snippet: &#34;Her proptosis and vision impairment were relieved after Endoscope-Navigation system (ENS)-aided optic canal decompression.&#34;
    explanation: This case report documents proptosis in Proteus syndrome.
- name: Visual impairment
  category: Ophthalmologic
  frequency: VERY_RARE
  phenotype_term:
    preferred_term: Visual impairment
    term:
      id: HP:0000505
      label: Visual impairment
  evidence:
  - reference: PMID:37975355
    supports: SUPPORT
    snippet: &#34;Her proptosis and vision impairment were relieved after Endoscope-Navigation system (ENS)-aided optic canal decompression.&#34;
    explanation: Vision impairment is reported among ocular manifestations.
- name: Neoplasm
  category: Oncologic
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Neoplasm
    term:
      id: HP:0002664
      label: Neoplasm
  evidence:
  - reference: DOI:10.1136/jmg-2024-110173
    supports: SUPPORT
    snippet: &#34;AKT1-related Proteus syndrome is an ultra-rare mosaic overgrowth disorder with tumour predisposition.&#34;
    explanation: This systematic review establishes tumor predisposition in Proteus syndrome.
  - reference: PMID:22876373
    supports: SUPPORT
    snippet: &#34;It is associated with a range of tumors, pulmonary complications, and a striking predisposition to deep vein thrombosis and pulmonary embolism.&#34;
    explanation: GeneReviews notes association with a range of tumors.
  - reference: PMID:38074478
    supports: SUPPORT
    snippet: &#34;We report a 35-year-old patient with PS, who underwent successful surgical removal of a well-differentiated SNEC obstructing his nasal cavity&#34;
    explanation: This case report documents sinonasal neuroendocrine carcinoma in Proteus syndrome.
biochemical: []
genetic:
- name: AKT1
  association: Causative
  notes: Somatic activating mosaic variant (c.49G&gt;A, p.Glu17Lys); HGNC:391
  evidence:
  - reference: DOI:10.1038/srep17162
    supports: SUPPORT
    snippet: &#34;A somatic activating mutation in AKT1, c.49G&gt;A, pGlu17Lys, that results in elevated AKT signaling in mutation-positive cells, is responsible for the mosaic overgrowth condition, Proteus syndrome.&#34;
    explanation: This identifies the causative somatic AKT1 variant.
  - reference: DOI:10.1093/hmg/ddz116
    supports: SUPPORT
    snippet: &#34;Proteus syndrome is a mosaic, progressive overgrowth disorder caused by a somatic activating variant c.49G &gt; A p.(E17K) in AKT1.&#34;
    explanation: This independently confirms the AKT1 p.E17K mosaic variant as the cause.
environmental: []
treatments:
- name: AKT inhibitor (miransertib/ARQ 092)
  description: &gt;-
    Allosteric pan-AKT inhibitor used to suppress AKT signaling and evaluated
    clinically for symptom and overgrowth control in Proteus syndrome.
  evidence:
  - reference: DOI:10.1038/srep17162
    supports: SUPPORT
    snippet: &#34;ARQ 092 reduced phosphorylation of AKT and downstream targets of AKT in a concentration-dependent manner in as little as two hours.&#34;
    explanation: This shows AKT pathway suppression by ARQ 092 in Proteus syndrome samples.
  - reference: DOI:10.1101/mcs.a006134
    supports: SUPPORT
    snippet: &#34;The patient has experienced sustained improvement of pain and slowed growth of bilateral plantar cerebriform connective tissue nevi.&#34;
    explanation: This case report describes clinical benefit with miransertib (ARQ 092).
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
    qualifiers:
    - predicate:
        preferred_term: therapeutic agent
        term:
          id: NCIT:C2259
          label: Therapeutic Agent
      value:
        preferred_term: miransertib
        term:
          id: NCIT:C99172
          label: Miransertib
- name: Surgical intervention
  description: Surgical debulking or corrective procedures used to manage focal overgrowth and deformity.
  evidence:
  - reference: DOI:10.1055/a-2300-7002
    supports: SUPPORT
    snippet: &#34;We report a case of PS in a two-year-old female patient with the following clinical features: unilateral overgrowth of connective tissue in the right buttock and right foot, where multiple surgeries were performed to achieve a desirable aesthetic outcome and ensure psychological comfort of the young patient.&#34;
    explanation: This case report documents surgical intervention for overgrowth management.
  treatment_term:
    preferred_term: surgical procedure
    term:
      id: MAXO:0000004
      label: surgical procedure
differential_diagnoses:
- name: Klippel-Trenaunay-Weber syndrome
  description: &gt;
    Overgrowth with vascular malformations can resemble Proteus syndrome and
    requires clinical and radiologic differentiation.
  distinguishing_features:
  - Capillary/venous malformations with limb hypertrophy and port-wine stains
  - Typically lacks cerebriform connective tissue nevi
  evidence:
  - reference: PMID:25009745
    supports: SUPPORT
    snippet: &#34;In the current review, four overgrowth syndromes were characterized (Proteus syndrome, Klippel-Trenaunay-Weber syndrome, Madelung&#39;s disease, and neurofibromatosis type I) and illustrated using cases from our institution.&#34;
    explanation: This review explicitly lists Klippel-Trenaunay-Weber syndrome alongside Proteus syndrome in differential evaluation of overgrowth syndromes.
- name: Madelung&#39;s disease (multiple symmetric lipomatosis)
  disease_term:
    preferred_term: multiple symmetric lipomatosis
    term:
      id: MONDO:0007908
      label: multiple symmetric lipomatosis
  description: &gt;
    Symmetric lipomatous overgrowth can resemble Proteus syndrome and should
    be differentiated based on distribution and accompanying malformations.
  distinguishing_features:
  - Symmetric lipomatous masses rather than mosaic, segmental overgrowth
  - Absence of cerebriform connective tissue nevi
  evidence:
  - reference: PMID:25009745
    supports: SUPPORT
    snippet: &#34;In the current review, four overgrowth syndromes were characterized (Proteus syndrome, Klippel-Trenaunay-Weber syndrome, Madelung&#39;s disease, and neurofibromatosis type I) and illustrated using cases from our institution.&#34;
    explanation: This review includes Madelung&#39;s disease among Proteus syndrome differentials.
- name: Neurofibromatosis type I
  disease_term:
    preferred_term: neurofibromatosis type 1
    term:
      id: MONDO:0018975
      label: neurofibromatosis type 1
  description: &gt;
    Neurocutaneous overgrowth and benign tumors can overlap with Proteus
    syndrome, but NF1 has distinct diagnostic features.
  distinguishing_features:
  - Cafe-au-lait macules and neurofibromas
  - Lisch nodules and NF1 pathogenic variants
  evidence:
  - reference: PMID:25009745
    supports: SUPPORT
    snippet: &#34;In the current review, four overgrowth syndromes were characterized (Proteus syndrome, Klippel-Trenaunay-Weber syndrome, Madelung&#39;s disease, and neurofibromatosis type I) and illustrated using cases from our institution.&#34;
    explanation: This review includes neurofibromatosis type I among overgrowth syndromes that overlap with Proteus syndrome.
- name: CLOVES syndrome
  disease_term:
    preferred_term: CLOVES syndrome
    term:
      id: MONDO:0013038
      label: CLOVES syndrome
  description: &gt;
    Segmental overgrowth with complex vascular and soft tissue malformations
    can overlap with Proteus syndrome presentations.
  distinguishing_features:
  - Typically congenital, with lipomatous truncal overgrowth and vascular malformations
  - PIK3CA-related overgrowth rather than AKT1 mosaic variant
  evidence:
  - reference: PMID:34668833
    supports: SUPPORT
    snippet: &#34;Discussion: CLOVES syndrome, neurofibromatosis 1 or PTEN hamartoma tumor syndrome are partially superimposable entities to Proteus syndrome and may generate diagnostic doubt.&#34;
    explanation: This case report lists CLOVES among overlapping entities in differential diagnosis.
- name: PTEN hamartoma tumor syndrome
  disease_term:
    preferred_term: PTEN hamartoma tumor syndrome
    term:
      id: MONDO:0017623
      label: PTEN hamartoma tumor syndrome
  description: &gt;
    PTEN-related overgrowth and hamartomatous features can mimic Proteus
    syndrome, requiring molecular differentiation.
  distinguishing_features:
  - Germline PTEN variants with systemic hamartomas and cancer predisposition
  - Macrocephaly and mucocutaneous findings typical of PHTS
  evidence:
  - reference: PMID:34668833
    supports: SUPPORT
    snippet: &#34;Discussion: CLOVES syndrome, neurofibromatosis 1 or PTEN hamartoma tumor syndrome are partially superimposable entities to Proteus syndrome and may generate diagnostic doubt.&#34;
    explanation: This case report highlights PTEN hamartoma tumor syndrome as a differential.
  - reference: PMID:20301661
    supports: SUPPORT
    snippet: &#34;The PTEN hamartoma tumor syndrome (PHTS) includes Cowden syndrome (CS), Bannayan-Riley-Ruvalcaba syndrome (BRRS), PTEN-related Proteus syndrome (PS), and PTEN-related Proteus-like syndrome.&#34;
    explanation: GeneReviews links PTEN hamartoma tumor syndrome to PTEN-related Proteus/Proteus-like presentations.
  - reference: PMID:40058215
    supports: SUPPORT
    snippet: &#34;PTEN hamartomas cause a variety of conditions, including Cowden syndrome, Bannayan-Riley-Ruvalcaba syndrome, PTEN-related Proteus syndrome, and Proteus-like syndrome.&#34;
    explanation: This case report reiterates PTEN-related Proteus syndromes within the PTEN hamartoma spectrum.
- name: Bannayan-Riley-Ruvalcaba syndrome
  disease_term:
    preferred_term: Bannayan-Riley-Ruvalcaba syndrome
    term:
      id: MONDO:0007924
      label: Bannayan-Riley-Ruvalcaba syndrome
  description: &gt;
    PTEN-related overgrowth syndrome that can overlap with Proteus-like
    features and should be distinguished by germline PTEN findings and classic
    mucocutaneous/hamartomatous manifestations.
  distinguishing_features:
  - Macrocephaly with hamartomatous polyposis and lipomas
  - Germline PTEN variants with systemic findings
  evidence:
  - reference: PMID:20301661
    supports: SUPPORT
    snippet: &#34;The PTEN hamartoma tumor syndrome (PHTS) includes Cowden syndrome (CS), Bannayan-Riley-Ruvalcaba syndrome (BRRS), PTEN-related Proteus syndrome (PS), and PTEN-related Proteus-like syndrome.&#34;
    explanation: GeneReviews includes BRRS within the PTEN hamartoma tumor syndrome spectrum relevant to Proteus differentials.
clinical_trials:
- name: NCT04316546
  phase: PHASE_II
  status: RECRUITING
  description: Multi-cohort Phase 2 dose-escalation study of miransertib (MK-7075) in Proteus syndrome.
  evidence:
  - reference: clinicaltrials:NCT04316546
    supports: SUPPORT
    snippet: &#34;To learn if miransertib is a safe and effective treatment for Proteus syndrome.&#34;
    explanation: The trial objective confirms evaluation of miransertib for Proteus syndrome.
- name: NCT02594215
  phase: PHASE_I
  status: COMPLETED
  description: Dose-finding study of MK-7075 (miransertib) in children and adults with Proteus syndrome.
  evidence:
  - reference: clinicaltrials:NCT02594215
    supports: SUPPORT
    snippet: &#34;To determine the safety, tolerability, and recommended dose of MK-7075 in people with PS.&#34;
    explanation: The trial objective defines dose-finding and safety assessment in Proteus syndrome.
- name: NCT03094832
  phase: PHASE_I
  status: TERMINATED
  description: Phase 1/2 open-label study of oral miransertib (MK-7075) in PROS and Proteus syndrome (MOSAIC).
  evidence:
  - reference: clinicaltrials:NCT03094832
    supports: SUPPORT
    snippet: &#34;This is an open label, Phase 1/2 study of oral miransertib (MK-7075) administered to participants at least 2 years of age with phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha (PIK3CA)-related Overgrowth Spectrum (PROS) and Proteus Syndrome (PS) (MOSAIC).&#34;
    explanation: The trial summary describes the Phase 1/2 MOSAIC study including Proteus syndrome.
- name: NCT04980872
  phase: PHASE_II
  status: ACTIVE_NOT_RECRUITING
  description: Extension study evaluating safety/tolerability of oral miransertib in PROS or Proteus syndrome.
  evidence:
  - reference: clinicaltrials:NCT04980872
    supports: SUPPORT
    snippet: &#34;This is a study of the safety and tolerability of oral miransertib (MK-7075) administered to participants at least 2 years of age with phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA)-related overgrowth spectrum (PROS) or Proteus Syndrome (PS).&#34;
    explanation: The study summary states the safety/tolerability focus for PROS or Proteus syndrome participants.
- name: NCT03317366
  phase: NOT_APPLICABLE
  status: UNKNOWN
  description: Expanded access for ARQ 092 (miransertib) in overgrowth diseases or vascular anomalies with PI3K/AKT alterations.
  evidence:
  - reference: clinicaltrials:NCT03317366
    supports: SUPPORT
    snippet: &#34;ARQ 092 is being investigated for patients with overgrowth diseases and/or vascular anomalies with genetic alterations of the PI3K/AKT pathway and may be available for patients who are ineligible for an ongoing ARQ 092 clinical trial or have other considerations that prevent access to ARQ 092 through an existing clinical trial.&#34;
    explanation: The summary describes expanded access for PI3K/AKT-pathway overgrowth disorders including Proteus syndrome.
- name: NCT00001403
  phase: NOT_APPLICABLE
  status: RECRUITING
  description: Natural history study of Proteus syndrome and related congenital overgrowth disorders.
  evidence:
  - reference: clinicaltrials:NCT00001403
    supports: SUPPORT
    snippet: &#34;This study will examine rare congenital disorders that involve malformations and abnormal growth. It will focus on patients with Proteus syndrome, whose physical features are characterized by overgrowth, benign tumors of fatty tissue or blood vessels, asymmetric arms or legs, and large feet with very thick soles.&#34;
    explanation: The study description states a natural history focus on Proteus syndrome.
datasets: []
</pre>
            </div>
        </div>

        <footer class="page-footer">
            <p>
                Generated from <a href="https://github.com/monarch-initiative/dismech" target="_blank">dismech</a>
                knowledge base
            </p>
            <p style="margin-top: 8px;">
                <a href="https://github.com/monarch-initiative/dismech/blob/main/kb/disorders/Proteus_syndrome.yaml" target="_blank">View source on GitHub</a>
            </p>
        </footer>
    </div>

    <script>
        function toggleYaml() {
            const content = document.getElementById('yamlContent');
            const toggleText = document.getElementById('yamlToggleText');
            content.classList.toggle('show');
            toggleText.textContent = content.classList.contains('show') ? 'click to hide' : 'click to show';
        }
    </script>
    <script>
        (function() {
            const banner = document.querySelector('.notice-banner');
            if (!banner) return;
            const dismiss = () => banner.remove();
            banner.addEventListener('click', dismiss);
            banner.addEventListener('keydown', (event) => {
                if (event.key === 'Enter' || event.key === ' ') {
                    event.preventDefault();
                    dismiss();
                }
            });
        })();
    </script>
</body>
</html>